### NCCN Guidelines Version 2.2015 Panel Members

**Ovarian Cancer**

**Panel Members**

*Robert J. Morgan, Jr., MD/Chair ‡
City of Hope Comprehensive Cancer Center*

Deborah K. Armstrong, MD/Vice Chair Ω †
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Ronald D. Alvarez, MD Ω
University of Alabama at Birmingham Comprehensive Cancer Center

Jamie N. Bakkum-Gamez, MD Ω
Mayo Clinic Cancer Center

Kian Behbakht, MD Ω
University of Colorado Cancer Center

Lee-may Chen, MD Ω
UCSF Helen Diller Family Comprehensive Cancer Center

Larry Copeland, MD Ω
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Marta Ann Crispens, MD Ω
Vanderbilt-Ingram Cancer Center

Oliver Dorigo, MD, PhD Ω
Stanford Cancer Institute

David M. Gershenson, MD Ω
The University of Texas MD Anderson Cancer Center

Heidi J. Gray, MD Ω
University of Washington Medical Center/Seattle Cancer Care Alliance

Rachel Grisham, MD †
Memorial Sloan Kettering Cancer Center

Ardeshir Hakam, MD ≠
Moffitt Cancer Center

Laura J. Havrilesky, MD Ω
Duke Cancer Institute

Carolyn Johnston, MD Ω
University of Michigan Comprehensive Cancer Center

Shashikant Lele, MD Ω
Roswell Park Cancer Institute

Lainie Martin, MD †
Fox Chase Cancer Center

Ursula A. Matulonis, MD Ω †
Dana-Farber/Brigham and Women's Cancer Center

David M. O'Malley, MD Ω
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Richard T. Penson, MD, MRCP †
Massachusetts General Hospital Cancer Center

Steven C. Plaxe, MD Ω
UC San Diego Moores Cancer Center

Matthew A. Powell, MD Ω
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Elena Ratner, MD Ω
Yale Cancer Center/Smilow Cancer Hospital

Steven W. Remmenga, MD Ω
Fred & Pamela Buffett Cancer Center

Paul Sabbatini, MD † ♠
Memorial Sloan Kettering Cancer Center

Joseph T. Santoso, MD Ω
St. Jude Children's Research Hospital/University of Tennessee Health Science Center

Theresa L. Werner, MD † ‡
Huntsman Cancer Institute at the University of Utah

Jennifer Burns
Miranda Hughes, PhD
Fayna Ferkle, PharmD

**NCCN Guidelines Panel Disclosures**

Ω Gynecology oncology
‡ Hematology/Hematology oncology
† Medical oncology
♠ Internal medicine
≠ Pathology
* Discussion writing committee member
### Clinical Trials

NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

### NCCN Categories of Evidence and Consensus

All recommendations are category 2A unless otherwise specified. See NCCN Categories of Evidence and Consensus.

### NCCN Guidelines for Patients®

Available at [www.nccn.org/patients](http://www.nccn.org/patients).

### Staging (ST-1)

- **Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer:**
  - Clinical Presentation, Workup, Primary Treatment (OV-1)
  - Diagnosis by Previous Surgery: Findings and Primary Treatment (OV-2)
  - Pathologic Staging, Primary Chemotherapy/Primary Adjuvant Therapy (OV-3)
  - Post-Primary Treatment: Secondary Adjuvant Therapy (OV-4)
  - Monitoring/Follow-Up, Recurrent Disease (OV-5)
  - Disease Status, Therapy for Persistent Disease or Recurrence (OV-6)

- **Principles of Surgery (OV-A)**
- **Principles of Chemotherapy (Ovarian, Fallopian Tube, and Primary Peritoneal Cancer) (OV-B)**
- **Management of Drug Reactions (OV-C)**
- **Acceptable Recurrence Therapies (OV-D)**

- **Less Common Ovarian Histopathologies:**
  - Clinical Presentation, Workup, Diagnosis (LCOH-1)
  - Malignant Germ Cell Tumors (LCOH-2)
  - Malignant Sex Cord-Stromal Tumors (LCOH-4)
  - Carcinosarcoma (Malignant Mixed Müllerian Tumors) (LCOH-5)
  - Ovarian Low Malignant Potential Tumors (Borderline Epithelial Ovarian Tumors) (LCOH-6)

- **Sex Cord-Stromal Tumors - WHO Histologic Classification (LCOH-A)**
- **Surveillance for Germ Cell and Sex Cord-Stromal Tumors (LCOH-B)**
- **Acceptable Primary and Recurrence Therapies (LCOH-C)**

---

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2015.
Updates in Version 2.2015 of the NCCN Guidelines for Ovarian Cancer from Version 1.2015 include:

MS-1
• The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2015 of the NCCN Guidelines for Ovarian Cancer from Version 3.2014 include:

OV-1
• After primary treatment, the following text was revised: "All patients with ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer should be referred for genetic risk evaluation if not previously done."
• The last line was added to footnote "h": "A referral to a gynecologic oncologist is also recommended for management of occult serous tubal intraepithelial carcinomas." (Also for OV-2)

OV-2
• For grade 2 and 3, after "suspect no residual disease," the primary treatment options were reordered as follows: "Completion surgery/surgical staging or chemotherapy for 6 cycles or completion surgery/surgical staging."
• For stage II, III, IV, suspect unresectable residual disease, the primary treatment was revised: "...Consider completion surgery after 3-6 cycles followed by..." and footnote "m" was revised: "Completion surgery after 3-4 cycles is preferred; however, surgery may be performed after 4-6 cycles based on the clinical judgment of the gynecologic oncologist. Surgery may be performed after 6 cycles.
• Footnote "i" was added: "Some pathologists recommend that ovarian cancer be graded either low-grade (most grade 1 serous tumors) or high-grade (most grade 2 or 3 serous tumors). See FIGO Guidelines (ST-5)." (Also for OV-3)

OV-3
• After primary treatment for all stages, the following was added: "Consider symptom management and best supportive care. See NCCN Guidelines for Palliative Care. Refer for palliative care assessment, if appropriate." (Also for OV-5, footnote "t")
• Footnote "o" was added: "See Discussion for more details about treatment of low-grade tumors."

OV-4
• Under secondary adjuvant therapy, postmission pazopanib was added as a category 2B recommendation.

OV-5
• For recurrent disease, imaging studies are recommended "as clinically indicated."

OV-6
• Therapy for Persistant Disease or Recurrence
  › For progression, stable or persistent disease on primary chemotherapy, the following revisions were made: "Clinical trial and/or Best supportive care only/palliative care only (See NCCN Guidelines for Palliative Care) and/or Recurrence therapy."
  › For complete remission and relapse <6 mo after stopping chemotherapy or stage II, III, and IV with partial response, the following revisions were made: "Clinical trial or Recurrence therapy and/or Best supportive care (See NCCN Guidelines for Palliative Care) Observe (category 2B)."

Continued on next page
Updates in Version 1.2015 of the NCCN Guidelines for Ovarian Cancer from Version 3.2014 include:

OV-C 1 of 7 (continued)

• Fourth bullet, the first sub-bullet was revised: "Patients and their families need to be counseled about the possibility of a drug reaction and the signs and symptoms of one, and about the signs and symptoms of an adverse reaction (either infusion or allergic). Patients should be told to report any signs and symptoms of a drug reaction, especially after they have left the clinic (ie, delayed rash)."

• Fifth bullet, the following sub-bullets were removed:
  ‣ Although desensitization is more commonly used after allergic drug reactions, it can also be used after infusion reactions.
  ‣ If a mild reaction has previously occurred to a platinum agent, great caution should be undertaken if desensitization is pursued (see Allergic Reactions).

OV-C 2 of 7

• Under Allergic Reactions
  ‣ The first bullet was revised: "Symptoms include: rash, edema, shortness of breath (bronchospasm), syncope or pre-syncope, chest pain, tachycardia, hives/itching, changes in blood pressure, nausea, vomiting, chills, and changes in bowel function and occasionally Patients with severe reactions may have the following symptoms: cardiac problems, bronchospasm, blood pressure changes that require treatment, and feeling of impending doom.

• Under the fifth bullet, the second sub-bullet was revised: "Patients who have had mild reactions may develop more serious reactions even when the platinum drug is slowly infused. The desensitization treatment of these patients should be managed by a physician with expertise and experience in platinum desensitization."

OV-C 4 of 7

• "Administer antihistamine" was changed to "administered H1 blocker antihistamine." (Also on OV-C 5 of 7 through OV-C 7 of 7)

OV-D 1 of 2 (continued)

• Footnote "g" was added: "For patients with deleterious germline BRCA-mutated (as detected by an FDA-approved test or other validated test performed in a CLIA-approved facility) advanced ovarian cancer who have been treated with three or more lines of chemotherapy."

Less Common Ovarian Histopathologies

LCOH-1

• Workup, sixth bullet was revised: "Ultrasound or chest/abdominal/pelvic CT as clinically indicated."

LCOH-3

• Under Recurrent/Persistent Disease, "residual tumor" was changed to "residual malignancy" and the subsequent treatment options were revised as follows: "Consider additional platinum-based chemotherapy (category 2A 2B) or Observe (category 2B)."

• The following footnotes were removed and the text was revised and added to LCOH-C under "Acceptable Primary Therapies":
  ‣ "For select patients with stage IB-III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used (3 courses of carboplatin 400 mg/m2 on day 1 plus etoposide 120 mg/m2 on days 1, 2, and 3 every 4 weeks)."
  ‣ "BEP (Bleomycin, 30 units per week; etoposide, 100 mg/m2/d daily for days 1–5; cisplatin 20 mg/m2 daily for days 1–5) for 3–4 cycles (category 2B for 3 versus 4 cycles). Recommend pulmonary function tests if considering bleomycin."

LCOH-8

• Recurrent disease, following "surgical evaluation + debulking if appropriate," changed from two options to three: "Noninvasive disease," "Invasive implants of low malignant potential," and "invasive carcinoma (low or high grade)."

• Invasive carcinoma, a revision was made under recurrence therapy: 
  "Treatment as epithelial ovarian cancer (category 2B for low grade)."

LCOH-B

• Radiographic imaging for germ cell tumors was changed from "not indicated" to "as clinically indicated."

LCOH-C

• Page title was revised: "Acceptable Primary and Recurrence Therapies."

• BEP and etoposide/carboplatin are now listed on this page as acceptable primary therapies for malignant germ cell tumors.

• Footnote "1" was added: "Recommend pulmonary function test if considering bleomycin."

ST-5

• This page was added to outline the updated FIGO staging guidelines for cancer of the ovary, Fallopian tube, and peritoneum.
NCCN Guidelines Version 2.2015
Epithelial Ovarian Cancer/Fallopian Tube Cancer/
Primary Peritoneal Cancer

CLINICAL PRESENTATION

Suspicious pelvic mass detected on abdominal/pelvic exam and/or ascites, abdominal distention, and/or symptoms such as bloating, pelvic pain, or urinary symptoms without other obvious source of malignancy.

WORKUP

- Obtain family history
- Refer for genetic risk evaluation
- Abdominal/pelvic exam
- Chest imaging
- Complete blood count (CBC), chemistry profile with liver function tests (LFT)
- GI evaluation
- Ultrasound and/or abdominal/pelvic CT/MRI
- CA-125 or other tumor markers

PRIMARY TREATMENT

Laparotomy/total abdominal hysterectomy (TAH)/bilateral salpingo-oophorectomy (BSO) with comprehensive staging or unilateral salpingo-oophorectomy (USO) (category 1 or 1C, all stages with comprehensive staging if patient desires fertility) or Cytoreductive surgery if clinical stage II, III, IV or Consider neoadjuvant chemotherapy (category 1) or primary interval cytoreduction (diagnosis by fine-needle aspiration [FNA], biopsy, or paracentesis) for patients with bulky stage III/IV who are poor surgical candidates due to high-risk comorbidity conditions or disease factors.

All patients with ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer should be referred for genetic risk evaluation.

Diagnosis by previous surgery or tissue biopsy (cytopathology)

- Obtain family history
- Refer for genetic risk evaluation
- Chest imaging
- CBC, chemistry profile with LFTs
- Institutional pathology review
- Ultrasound and/or abdominal/pelvic CT/MRI
- CA-125 or other tumor markers

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

c) See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.
d) Primary treatment should not be delayed for a genetic counseling referral.
e) PET/CT scan or MRI may be indicated for indeterminate lesions if results will alter management.
f) For rare tumors including clear cell, mucinous, or low grade, see Discussion.
g) Standard recommendation includes a patient evaluation by a gynecologic oncologist prior to initiating chemotherapy. Published data demonstrate that primary assessment and debulking by a gynecologic oncologist result in a survival advantage. Patients being evaluated for neoadjuvant chemotherapy should be seen by a fellowship-trained gynecologic oncologist prior to being considered a poor surgical candidate. A referral to a gynecologic oncologist is also recommended for management of occult serous tubal intraepithelial carcinomas.

h) All women undergoing surgery for ovarian cancer should be counseled about the clinical benefit associated with combined IV and IP chemotherapy administration prior to surgery. NCI Clinical Announcement.

See Principles of Surgery (OV-A).

See Principles of Chemotherapy (OV-B) and Management of Drug Reactions (OV-C).
DIAGNOSIS BY PREVIOUS SURGERY

**Adequate previous surgery and staging**

- Suspected stage IA or IB, grade 1
  - Surgical staging

- Suspected stage IA or IB, grade 2
  - If observation considered
    - Surgical staging
  - Suspect residual disease
    - Completion surgery/surgical staging
  - Suspect no residual disease
    - Completion surgery/surgical staging or chemotherapy for 6 cycles

- Suspected stage IA or IB, grade 3 or clear cell or stage IC
  - Suspect residual disease
    - Completion surgery/surgical staging
  - Suspect no residual disease
    - Completion surgery/surgical staging or chemotherapy for 6 cycles

- Suspect potentially resectable residual disease
  - Tumor reductive surgery

- Stage II, III, IV
  - Suspect unresectable residual disease
    - Chemotherapy for a total of 6–8 cycles
    - Consider completion surgery after 3 cycles followed by postoperative chemotherapy

**Incomplete previous surgery and/or staging:**

1. Uterus intact
2. Adnexa intact
3. Omentum not removed
4. Documentation of staging incomplete
5. Residual disease, potentially resectable
6. Occult invasive carcinoma found at time of risk reduction surgery

- Suspected stage IA or IB, grade 1
  - Surgical staging

- Suspected stage IA or IB, grade 2
  - If observation considered
    - Surgical staging
  - Suspect residual disease
    - Completion surgery/surgical staging
  - Suspect no residual disease
    - Completion surgery/surgical staging or chemotherapy for 6 cycles

- Suspected stage IA or IB, grade 3 or clear cell or stage IC
  - Suspect residual disease
    - Completion surgery/surgical staging
  - Suspect no residual disease
    - Completion surgery/surgical staging or chemotherapy for 6 cycles

- Suspect potentially resectable residual disease
  - Tumor reductive surgery

- Stage II, III, IV
  - Suspect unresectable residual disease
    - Chemotherapy for a total of 6–8 cycles
    - Consider completion surgery after 3 cycles followed by postoperative chemotherapy

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PATHOLOGIC STAGING

Grade 1
- Stage IA or IB
- Observe

Grade 2
- Observe or
- Intravenous (IV) taxane/carboplatin for 3–6 cycles

Grade 3 or clear cell

Stage IC
- Grade 1, 2, or 3
- IV taxane/carboplatin for 3–6 cycles

PRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPY

- Consider symptom management and best supportive care. See NCCN Guidelines for Palliative Care. Refer for palliative care assessment, if appropriate.

Stage II
- Completion surgery as indicated by tumor response and potential resectability in selected patients

Stage III
- Chemotherapy
  - Intraperitoneal (IP) chemotherapy in <1 cm optimally debulked stage II and stage III patients (category 1 for stage III)
  - IV taxane/carboplatin for a total of 6–8 cycles (category 1)

Stage IV

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
STAGE II, III, IV
POST-PRIMARY TREATMENT

SECONDARY ADJUVANT THERAPY

Stage II, III, IV post-primary treatment

Complete clinical remission

Clinical trial or Observe or Postremission pazopanib (category 2B) or Postremission paclitaxel (category 3)

See Monitoring/ Follow-Up (OV-5)

Partial remission or progression

See Persistent Disease or Recurrence Therapy (OV-6)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
STAGE I-IV COMPLETE RESPONSE

MONITORING/FOLLOW-UP

- Visits every 2–4 mo for 2 y, then 3–6 mo for 3 y, then annually after 5 y
- Physical exam including pelvic exam
- CA-125® or other tumor markers if initially elevated
- Refer for genetic risk evaluation, if not previously done
- CBC and chemistry profile as indicated
- Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated
- Chest x-ray as indicated

RECURRENT DISEASE

- Rising CA-125, no previous chemotherapy or Clinical relapse, no previous chemotherapy
- Imaging studies as clinically indicated:
  - Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET)

STAGE I-IV COMPLETE RESPONSE

MONITORING/FOLLOW-UP

- Visits every 2–4 mo for 2 y, then 3–6 mo for 3 y, then annually after 5 y
- Physical exam including pelvic exam
- CA-125® or other tumor markers if initially elevated
- Refer for genetic risk evaluation, if not previously done
- CBC and chemistry profile as indicated
- Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated
- Chest x-ray as indicated

RECURRENT DISEASE

- Rising CA-125, no previous chemotherapy or Clinical relapse, no previous chemotherapy
- Imaging studies as clinically indicated:
  - Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET)

STAGE I-IV COMPLETE RESPONSE

MONITORING/FOLLOW-UP

- Visits every 2–4 mo for 2 y, then 3–6 mo for 3 y, then annually after 5 y
- Physical exam including pelvic exam
- CA-125® or other tumor markers if initially elevated
- Refer for genetic risk evaluation, if not previously done
- CBC and chemistry profile as indicated
- Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET) as clinically indicated
- Chest x-ray as indicated

RECURRENT DISEASE

- Rising CA-125, no previous chemotherapy or Clinical relapse, no previous chemotherapy
- Imaging studies as clinically indicated:
  - Chest/abdominal/pelvic CT, MRI, PET-CT, or PET (category 2B for PET)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
## DISEASE STATUS\(^e\)

- **Progression, stable, or persistent disease on primary chemotherapy**
- **Complete remission and relapse <6 mo after stopping chemotherapy**
- **Stage II, III, and IV with partial response**
- **Complete remission and relapse ≥6 mo after stopping chemotherapy**
  - **Radiographic and/or clinical relapse**
  - **Biochemical relapse (rising CA-125 and no radiographic evidence of disease)**

## THERAPY FOR PERSISTENT DISEASE OR RECURRENCE\(^u,v,w\)

- **Clinical trial\(^x\)**
- **Best supportive care only (See NCCN Guidelines for Palliative Care)**
- **Recurrence therapy\(^u,w\)**

- **Clinical trial\(^x\)**
- **Recurrence therapy\(^u,w\)**
- **Best supportive care (See NCCN Guidelines for Palliative Care)**

- **Consider secondary cytoreductive surgery\(^j\)**

- **Clinical trial\(^x\)**
  - **Combination platinum-based chemotherapy\(^u,w\)** preferred for first recurrence (category 1)
  - **Recurrence therapy\(^u,w\)**

- **Clinical trial\(^x\)**
  - **Delay treatment until clinical relapse**
  - **Immediate treatment for recurrent disease (recurrence therapy\(^w\))** (category 2B)

---

\(^e\)See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.

\(^u\)See Principles of Surgery (OV-A).

\(^v\)See Acceptable Recurrence Therapies (OV-D).

\(^w\)See Ancillary Palliative Surgical Procedures in Principles of Surgery (OV-A 3 of 3).

\(^x\)Clinical trials with newer agents should be strongly considered.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
General Considerations

• An open laparotomy including a vertical midline abdominal incision should be used in patients with a suspected malignant ovarian/Fallopian tube/primary peritoneal neoplasm in whom a surgical staging procedure, a primary debulking procedure, an interval debulking procedure, or secondary cytoreduction is planned.

• Intraoperative pathologic evaluation with frozen sections may assist in management.

• For select patients, a minimally invasive surgical approach may be employed by an experienced surgeon to achieve the surgical staging and debulking principles subsequently described.

• Patients who are unable to be optimally debulked using minimally invasive techniques should be converted to an open procedure.

• Minimally invasive surgical approaches may be useful when evaluating whether maximum cytoreduction can be achieved in patients with newly diagnosed or recurrent ovarian cancer. If clinical judgment indicates that maximum cytoreduction cannot be achieved, neoadjuvant chemotherapy should be considered.

• It is recommended that a gynecologic oncologist perform the appropriate surgery.

Operative Reports:

• Surgeons should describe the following in the operative report:
  ‣ Extent of initial disease before debulking pelvis, midabdomen, or upper abdomen (cutoffs: pelvic brim to lower ribs).
  ‣ Amount of residual disease in the same areas after debulking.
  ‣ Complete or incomplete resection; if incomplete, indicate the size of the major lesion and total number of lesions. Indicate if miliary or small lesions.

Continued on OV-A (2 of 3)

PRINCIPLES OF SURGERY (2 of 3)\(^1\)

Newly diagnosed invasive epithelial ovarian cancer apparently confined to an ovary or to the pelvis:
- On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for peritoneal cytologic examinations.
- All peritoneal surfaces should be visualized, and any peritoneal surface or adhesion suspicious for harboring metastasis should be selectively excised or biopsied. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis, paracolic gutters, and undersurfaces of the diaphragm (diaphragm scraping for Papanicolaou stain is an acceptable alternative).
- BSO and hysterectomy should be performed with every effort to keep an encapsulated mass intact during removal.
- For selected patients desiring to preserve fertility, USO may be considered.
- Omentectomy should be performed.
- Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels.
- The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve.\(^2\)

Newly diagnosed invasive epithelial ovarian cancer involving the pelvis and upper abdomen:
In general, every effort should be made to achieve maximum cytoreduction. Residual disease <1 cm defines optimal cytoreduction; however, maximal effort should be made to remove all gross disease since this offers superior survival outcomes.\(^3\)
- Aspiration of ascites (if present) should be performed for peritoneal cytologic examinations. All involved omentum should be removed.
- Suspicious and/or enlarged nodes should be resected, if possible.
- Those patients with tumor nodules outside the pelvis ≤2 cm (presumed stage IIIB) should have bilateral pelvic and para-aortic lymph node dissection as previously described.
- Procedures that may be considered for optimal surgical cytoreduction (in all stages) include bowel resection and/or appendectomy, stripping of the diaphragm or other peritoneal surfaces, splenectomy, partial cystectomy and/or ureteroneocystotomy, partial hepatectomy, partial gastrectomy, cholecystectomy, and/or distal pancreatectomy.
- Select patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for IP therapy. In these patients, consideration should be given to placement of IP catheter with initial surgery.


Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol (BRCA/HBOC syndrome)

• Perform operative laparoscopy.
• Survey upper abdomen, bowel surfaces, omentum, appendix (if present), and pelvic organs.
• Biopsy any abnormal peritoneal findings.
• Obtain pelvic washing for cytology. (50 cc normal saline instilled and aspirated immediately)
• Perform total BSO, removing 2 cm of proximal ovarian vasculature/IP ligament, all tube up to the cornua, and all peritoneum surrounding the ovaries and tubes, especially peritoneum underlying areas of adhesion between tube and/or ovary and the pelvic sidewall.4
• Engage in minimal instrument handling of the tubes and ovaries to avoid traumatic exfoliation of cells.4
• Both ovaries and tubes should be placed in an endobag for retrieval from the pelvis.
• Both ovaries and tubes should be processed according to SEE-FIM protocol.5
• If occult malignancy or STIC identified, provide referral to gynecologic oncologist.

Special Circumstances

• Fertility-sparing surgery: USO preserving the uterus and contralateral ovary (fertility-sparing surgery) can be considered for patients with apparent early-stage disease and/or good-risk tumors (early-stage invasive epithelial tumors, low malignant potential [LMP] lesions, malignant germ cell tumors, or malignant sex cord-stromal tumors) who wish to preserve fertility. Comprehensive surgical staging should still be performed to rule out occult higher stage disease but may be omitted in pediatric/adolescent patients with clinically apparent early-stage malignant germ cell tumors based on the pediatric surgical literature.
• Mucinous tumors: Primary invasive mucinous tumors of the ovary are uncommon. Thus, the upper and lower GI tract should be carefully evaluated to rule out an occult GI primary with ovarian metastases, and an appendectomy should be performed in patients with a mucinous ovarian neoplasm.
• LMP tumors: Although data show upstaging with lymphadenectomy, other data show that lymphadenectomy does not affect overall survival. However, omentectomy and multiple biopsies of peritoneum (the most common sites of peritoneal implants) may upstage patients in approximately 30% of cases and may affect prognosis.
• Secondary cytoreduction: A secondary cytoreduction procedure can be considered in patients with recurrent ovarian cancer who recur more than 6–12 months since completion of initial chemotherapy, have an isolated focus (or limited foci) of disease amenable to complete resection, and do not have ascites. Patients are encouraged to participate in ongoing trials evaluating the true benefit of secondary cytoreduction.

Ancillary Palliative Surgical Procedures

These procedures may be appropriate in select patients:
• Paracentesis/indwelling peritoneal catheter
• Thoracentesis/pleurodesis/video-assisted thoracoscopy/indwelling pleural catheter
• Ureteral stents/nephrostomy
• Gastrostomy tube/intestinal stents/surgical relief of intestinal obstruction


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
General
• Patients with ovarian, Fallopian tube, or peritoneal cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment.
• Prior to the initiation of any therapy:
  ▶ Patients of child-bearing potential who desire fertility-sparing procedures should be referred to an appropriate fertility specialist. (See NCCN Guidelines for Adolescent and Young Adult Oncology)
  ▶ Goals of systemic therapy should be discussed.
• Prior to recommending chemotherapy, requirements for adequate organ function and performance status should be met.
• Patients should be observed closely and treated for any complications during chemotherapy. Appropriate blood chemistry tests should be monitored. Appropriate dose reductions and modifications of chemotherapy should be performed depending on toxicities experienced and goals of therapy.
• After completion of chemotherapy, patients should be assessed for response during and following treatment and monitored for any long-term complications.
• Chemosensitivity/resistance and/or other biomarker assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy in situations where there are multiple equivalent chemotherapy options available. The current level of evidence is not sufficient to supplant standard-of-care chemotherapy. (category 3)

For patients with newly diagnosed ovarian, Fallopian tube, or primary peritoneal cancer:
• If they are eligible for chemotherapy, patients should be informed about the different options that are available--that is, IV chemotherapy, a combination of IP and IV chemotherapy, or a clinical trial--so they can decide which is the most the appropriate option. (See OV-B 3 of 3 for dosing and schedule of these regimens).
• Prior to the administration of the combined IP and IV regimen, patients must be apprised of the increased toxicities with the combined regimen when compared to using IV chemotherapy alone (increased myelosuppression, renal toxicities, abdominal pain, neuropathy, GI toxicities, metabolic toxicities, and hepatic toxicities).
• Patients considered for the IP cisplatin and IP/IV paclitaxel regimen should have normal renal function prior to starting, a medically appropriate performance status based on the future toxicities of the IP/IV regimen, and no prior evidence of medical problems that could significantly worsen during chemotherapy (eg, pre-existing neuropathy).
• Prior to receiving and after receiving each cycle of IP cisplatin, adequate amounts of IV fluids need to be administered in order to prevent renal toxicity. After each cycle has been completed, patients need to be monitored carefully for myelosuppression, dehydration, electrolyte loss, end-organ toxicities (such as renal and hepatic damage), and all other toxicities. Patients often require IV fluids postchemotherapy in the outpatient setting to prevent or help treat dehydration.
• Refer to the original references (See Discussion) for full toxicity data, doses, schedule, and dose modifications.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
For patients who have recurrent ovarian, Fallopian tube, or primary peritoneal cancer:

• Refer to the original references (See Discussion) for full toxicity data, doses, schedule, and dose modifications.

• Patients should be informed about the following:
  1) Availability of clinical trials, including the risks and benefits of various treatments, which will depend on the number of prior lines of chemotherapy the patient has received, and
  2) The patient’s performance status, end-organ status, and pre-existing toxicities from prior regimens. If appropriate, palliative care should also be discussed as a possible treatment choice. See NCCN Guidelines for Palliative Care.

• Because of prior platinum exposure, myelosuppression occurs more frequently with any myelotoxic agent given in the recurrent setting.

• With repeat use of either carboplatin and/or cisplatin, patients are at an increased risk of developing a hypersensitivity reaction (also called an allergic reaction) that could be life-threatening. Thus, patients should be counseled about the risk that a hypersensitivity reaction may occur, educated about the signs and symptoms of hypersensitivity reactions, treated by medical staff who know how to manage hypersensitivity reactions, and treated in a medical setting where appropriate medical equipment is available in case of an allergic reaction. See Management of Drug Reactions (OV-C).

• Before any chemotherapy drug is given in the recurrent setting, the clinician should be familiar with the drug’s metabolism (ie, renal, hepatic) and should make certain that the patient is an appropriate candidate for the drug (eg, that the patient has adequate renal or hepatic function).

• Clinicians should be familiar with toxicity management and appropriate dose reduction.

• The schedule, toxicity, and potential benefits of any treatment should be thoroughly discussed with the patient and caregivers. Patient education should also include a discussion of precautions and measures to reduce the severity and duration of complications.

For elderly patients (>age 65) and/or those with comorbidities

• Elderly patients and those with comorbidities may be intolerant to the combination chemotherapy regimens recommended in these NCCN Guidelines. Single-agent platinum agents may be appropriate in selected patients.

  ▶ Algorithms have been developed for predicting chemotherapy toxicity. See the NCCN Guidelines for Older Adult Oncology.

Definitions used in the NCCN Guidelines for Ovarian Cancer

• Adjuvant therapy: Drugs, radiation, or other forms of supplemental treatment following cancer surgery intended to decrease the risk of disease recurrence or to primarily treat residual disease, whether gross or microscopic, following surgical cytoreduction.

• Neo-adjuvant therapy: Drugs, radiation, or other forms of treatment given prior to cancer surgery intended to reduce tumor burden in preparation for surgery.

• Recurrence therapy: Drugs, radiation, or other forms of treatment used to treat recurrent cancer, control symptoms, or increase length and/or quality of life at the time of clinical, biochemical, or radiographic evidence of recurrent cancer following the initial treatment.
PRINCIPLES OF CHEMOTHERAPY (3 of 3)
(FOR OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER)

PRIMARY CHEMOTHERAPY/PRIMARY ADJUVANT THERAPY REGIMENS FOR STAGE II-IV

1. IP/IV Regimen
   - Paclitaxel 135 mg/m² IV continuous infusion over 3 or 24 h Day 1; cisplatin 75–100 mg/m² IP, Day 2 after IV paclitaxel; paclitaxel 60 mg/m² IP Day 8. Repeat every 3 weeks x 6 cycles. (category 1)

2. IV Regimens
   - Paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5–6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Dose-dense paclitaxel 80 mg/m² IV over 1 hour Days 1, 8, and 15 followed by carboplatin AUC 5–6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Paclitaxel 60 mg/m² IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes. Weekly for 18 weeks. (category 1)
   - Docetaxel 60–75 mg/m² IV over 1 hour followed by carboplatin AUC 5–6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. (category 1)
   - Bevacizumab-containing regimens per ICON-7 and GOG-218:
     - Paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5–6 IV over 1 hour, and bevacizumab 7.5 mg/kg IV over 30–90 minutes Day 1. Repeat every 3 weeks x 5–6 cycles. Continue bevacizumab for up to 12 additional cycles. (category 3)
     - Paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour Day 1. Repeat every 3 weeks x 6 cycles. Starting Day 1 of cycle 2, give bevacizumab 15 mg/kg IV over 30–90 minutes every 3 weeks for up to 22 cycles. (category 3)

See Management (OV-3)

---

1 See Discussion for references.
2 IV regimens may be considered for neoadjuvant therapy.
3 The published randomized trial regimen used IV continuous infusion paclitaxel over 24 h.
4 Due to changes in creatinine methodology, changes regarding carboplatin dosing can be considered. See FDA carboplatin dosing statement.
5 This regimen may be considered for elderly patients or those with poor performance status.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
MANAGEMENT OF DRUG REACTIONS (1 of 7)

Overview

- Virtually all drugs used in oncology have the potential to cause adverse drug reactions while being infused, which can be classified as either infusion or allergic reactions.\(^1\)
  - Infusion reactions are often characterized by milder symptoms (e.g., hot flushing, rash).
  - Hypersensitivity (allergic) reactions are often characterized by more severe symptoms (e.g., shortness of breath, generalized hives/itching, changes in blood pressure).
- Most adverse drug reactions that occur are mild reactions, but more severe reactions can occur.\(^2,3\)
  - Anaphylaxis is a rare type of very severe allergic reaction that can occur with the platinum and taxane agents (and others less commonly), can cause cardiovascular collapse, and can be life threatening.\(^4-6\)
  - Drug reactions can occur either during the infusion or following completion of the infusion (and can even occur days later).
- In gynecologic oncology treatment, drugs that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel.\(^1\)
  - Adverse reactions associated with taxane drugs (i.e., docetaxel, paclitaxel) and biotherapeutic agents tend to be infusion related often attributed to cremophor in paclitaxel and tend to occur during the first few cycles of treatment (although they can be seen during any infusion regardless of how many previous cycles were administered).
  - Adverse reactions associated with platinum drugs (i.e., carboplatin, cisplatin), a true allergy, tend to occur following re-exposure to the inciting drug or less commonly at the completion of initial chemotherapy (i.e., cycle 6 of a planned 6 treatments).\(^3\)
- Preparation for a possible drug reaction
  - Patients and their families should be counseled about the possibility of a drug reaction and the signs and symptoms of one. Patients should be told to report any signs and symptoms of a drug reaction, especially after they have left the clinic (i.e., delayed rash).
  - Clinicians and nursing staff should be prepared for the possibility of a drug reaction every time a patient is infused with a drug. Standing orders should be written for immediate intervention in case a severe drug reaction occurs and the treatment area should have appropriate medical equipment in case of a life-threatening reaction.\(^5\)
  - Epinephrine (intramuscular 0.3 mL of 1 mg/mL solution/Epipen) should be used for any patient experiencing hypotension (systolic BP of <90 mm Hg) with or without other symptoms of an allergic/hypersensitivity reaction during or shortly after any chemotherapy drug treatment. In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.
- Desensitization refers to a process of rendering the patient less likely to respond to an allergen and can be considered an option for patients who have had drug reactions.\(^1,7-9\)
  - If a patient has previously had a very severe life-threatening reaction, the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.

References on OV-C 3 of 7

Continued on OV-C 2 of 7
Management of Drug Reactions (2 of 7)

Infusion Reactions

- Symptoms include: hot flushing, rash, fever, chest tightness, mild blood pressure changes, back pain, and chills.
- Symptoms usually can be treated by decreasing the infusion rate and resolve quickly after stopping the infusion. However, patients who have had mild reactions to carboplatin, cisplatin, or oxaliplatin may develop more serious reactions even when the platinum drug is slowly infused; therefore, consider consultation with an allergist.
- More common with paclitaxel (27% of patients); however, mild reactions can occur with liposomal doxorubicin.
- If an infusion reaction has previously occurred to a taxane:
  - For mild infusion reactions (e.g., flushing, rash, chills), patients may be rechallenged with the taxane if:
    1) the patient, physician, and nursing staff are all comfortable with this plan;
    2) the patient has been counseled appropriately; and
    3) emergency equipment is available in the clinic area.
  - Typically the taxane infusion can be re-started at a much slower rate, and the rate can be slowly increased as tolerated as per the treating clinician’s judgment. Note that this slow infusion is different from desensitization.
  - Many institutions have nursing policies that stipulate how to reinfuse the drug if the patient has had a prior infusion reaction.

Allergic Reactions (i.e., True Drug Allergies)

- Symptoms include: rash, edema, shortness of breath (bronchospasm), syncope or pre-syncope, chest pain, tachycardia, hives/itching, changes in blood pressure, nausea, vomiting, chills, and changes in bowel function and occasionally feeling of impending doom.
- Symptoms may continue to persist after stopping infusion and/or after treatment interventions.
- More common with platinum drugs such as carboplatin (16% of patients), cisplatin, and oxaliplatin. Mild reactions can occur with platinum agents.
- Patients who are at higher risk of developing a hypersensitivity (allergic) reaction include those in the following settings:
  - Re-introduction of the drug after a period of no exposure and following multiple cycles of the drug during the first and subsequent exposures
  - IV administration of the drug rather than oral or IP administration
  - With allergies to other drugs
  - Those who have previously had a reaction
- If an allergic reaction has previously occurred:
  - Consider consultation with an allergist (or qualified medical or gynecologic oncologist) and skin testing for patients who have experienced a platinum reaction (e.g., carboplatin-hypersensitivity reaction).
  - Patients who have had mild reactions may develop more serious reactions even when the platinum drug is slowly infused.
  - For very severe life-threatening reactions (i.e., anaphylaxis), the implicated drug should not be used again unless under guidance of an allergist or specialist with desensitization experience.
  - For more severe reactions—such as those involving blood pressure changes, dyspnea, tachycardia, widespread urticaria, or hypoxia—the treating clinician should consult an allergist or specialist with desensitization expertise prior to rechallenge.
  - If it is appropriate to give the drug again, patients should be desensitized prior to resuming chemotherapy even if the symptoms have resolved. Patients must be desensitized with each infusion if they previously had a drug reaction.
MANAGEMENT OF DRUG REACTIONS (3 of 7)

REFERENCES


See Drug Reaction to Platinum Agents on OV-C 4 of 7

See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7
**DRUG REACTION TO PLATINUM AGENTS**

**REACTION**

<table>
<thead>
<tr>
<th>First exposure (platinum naive)</th>
<th>Second exposure or further exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild reaction</strong>¹ (hot flushing, rash, pruritus)</td>
<td><strong>Severe reaction</strong>² (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting])</td>
</tr>
<tr>
<td><strong>Life-threatening reaction</strong>² (IE, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting])</td>
<td></td>
</tr>
</tbody>
</table>

**MANAGEMENT OF DRUG REACTIONS (4 of 7)**

1. **First exposure (platinum naive)**
   - Decrease the infusion rate
   - Symptoms often resolve quickly after stopping infusion
   - Administer H1 blocker antihistamine³

2. **Second exposure or further exposure**
   - Stop infusion
   - Administer H1 blocker antihistamine³ to treat symptoms
   - Corticosteroid ± IM epinephrine⁴ if symptoms do not quickly resolve

**MANAGEMENT/TREATMENT³**

3. Consider allergy consultation⁵
4. If staff agree and vital signs remain stable, rechallenge with platinum drug
   - Administer premedication with H1 blocker antihistamine, corticosteroids, H2 blockers³
5. Consider allergy consultation
6. Do not rechallenge/readminister drug until evaluated by allergist or specialist with desensitization expertise
7. Potential candidate for desensitization⁶,⁷ with each infusion

**MANAGEMENT OF DRUG REACTIONS (4 of 7)**

**See OV-C 5 of 7**

---

¹Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

²Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

³H1 blocker antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

⁴In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

⁵Mild reactions can progress to severe reactions by re-exposure. An allergy consultation may provide skin testing and evaluate sensitization and the risk for further, more severe reactions.

⁶Referral to academic center with expertise in desensitization is preferred.


---

**See Drug Reaction to Taxane, Liposomal Doxorubicin, or Biotherapeutic Agents on OV-C 6 of 7**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**DRUG REACTION TO PLATINUM AGENTS**

**MANAGEMENT OF DRUG REACTIONS (5 of 7)**

<table>
<thead>
<tr>
<th>REACTION</th>
<th>MANAGEMENT/TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild reaction&lt;sup&gt;1&lt;/sup&gt; (hot flushing, rash, pruritus)</td>
<td>See OV-C 4 of 7</td>
</tr>
</tbody>
</table>
| Severe reaction<sup>2</sup> (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting]) | • Stop infusion  
• Administer oxygen, nebulized bronchodilators, H1 blocker antihistamine, H2 blockers, corticosteroid; IM epinephrine<sup>4</sup> if needed |
| Life-threatening reaction<sup>2</sup> (ie, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting]) | • Stop infusion  
• Administer IM epinephrine<sup>4</sup>, oxygen, nebulized bronchodilators, H1 blocker antihistamine, H2 blockers, corticosteroid<sup>3</sup>  
• Saline bolus, if needed  
|• Consider allergy consultation  
• Do not rechallenge/readminister drug until evaluated by allergist or specialist with desensitization expertise  
• Potential candidate for desensitization<sup>6,7</sup> with each infusion |

<sup>1</sup>Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup>Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup>H<sub>1</sub> blocker antihistamine (eg, diphenhydramine or hydroxyzine); H<sub>2</sub> blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>4</sup>In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

<sup>4</sup>Referral to academic center with expertise in desensitization is preferred.


<sup>8</sup>For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.
### DRUG REACTION TO TAXANE, LIPOSOMAL DOXORUBICIN, OR BIOTHERAPEUTIC AGENTS

<table>
<thead>
<tr>
<th>REACTION</th>
<th>MANAGEMENT/TREATMENT</th>
</tr>
</thead>
</table>
| Mild reaction<sup>1</sup> (hot flushing, rash, pruritus, pain in chest/abdomen/pelvis/back) | • Stop infusion  
  ‣ Symptoms often resolve quickly after stopping infusion  
  ‣ Administer H1 blocker antihistamine<sup>3</sup> to treat symptoms |
| Severe reaction<sup>2</sup> (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong) | • If staff agree and vital signs remain stable, rechallenge with drug at slower infusion rate<sup>9</sup>  
  ‣ Administer premedication with H1 blocker antihistamine, corticosteroids, H2 blockers<sup>5</sup> |
| Life-threatening reaction<sup>2</sup> (ie, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/anxiety/something wrong) | • If repeat mild reaction, then do not rechallenge/readminister  
  • Potential candidate for desensitization<sup>7,9</sup> with each infusion |

---

<sup>1</sup>Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup>Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup>H1 blocker antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).


<sup>9</sup>Consider switching to docetaxel; however, there are no data to support switching taxanes. Cross reactions have occurred and have been life-threatening. Some reactions to paclitaxel may occur because of the diluent.
### DRUG REACTION TO TAXANE, LIPOSOMAL DOXORUBICIN, OR BIOOTHERAPEUTIC AGENTS

#### MANAGEMENT OF DRUG REACTIONS (7 of 7)

<table>
<thead>
<tr>
<th>REACTION</th>
<th>MANAGEMENT/TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild reaction</strong>&lt;sup&gt;1&lt;/sup&gt; (hot flushing, rash, pruritus, pain in chest/abdomen/pelvis/back)</td>
<td><strong>See OV-C 6 of 7</strong></td>
</tr>
</tbody>
</table>
| **Severe reaction**<sup>2</sup> (shortness of breath, changes in blood pressure requiring treatment, dyspnea, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/ anxiety/something wrong) | • Stop infusion  
• Administer oxygen, nebulized bronchodilator, H1 blocker antihistamine, H2 blockers, corticosteroid;**3** IM epinephrine if needed**4** |
| **Life-threatening reaction**<sup>2</sup> (ie, anaphylaxis) (acute onset, generalized hives, respiratory compromise, severe hypotension, GI symptoms [nausea, vomiting], pain in chest/abdomen/pelvis/back, feeling of impending doom/ anxiety/something wrong) | • Stop infusion  
• Administer IM epinephrine,**4** oxygen, nebulized bronchodilator, H1 blocker antihistamine, H2 blockers, corticosteroid**3**  
• Do not rechallenge/readminister drug until evaluated by allergist or specialist with desensitization expertise  
• Potential candidate for desensitization**6,7** with each infusion |

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

<sup>1</sup>Most mild reactions are infusion reactions and more commonly are caused by taxanes (ie, docetaxel, paclitaxel), but can also occur with platinum agents (ie, carboplatin, cisplatin).

<sup>2</sup>Most severe reactions are allergic reactions and more commonly are caused by platinum agents.

<sup>3</sup>H1 blocker antihistamine (eg, diphenhydramine or hydroxyzine); H2 blockers (eg, cimetidine, famotidine); corticosteroids (eg, methylprednisolone, hydrocortisone, dexamethasone).

<sup>4</sup>In the setting of acute cardiopulmonary arrest, standard resuscitation (ACLS) procedures should be followed.

<sup>5</sup>Refer to academic center with expertise in desensitization is preferred.


<sup>7</sup>For both taxanes and platinum analogues, it is preferred that anyone with a life-threatening reaction be evaluated and referred to an academic center if the drug is still considered first line.
## ACCEPTABLE RECURRENCE THERAPIES (1 OF 2)\(^a\)

<table>
<thead>
<tr>
<th>Preferred Single Agents or Combinations</th>
<th>Cytotoxic Therapy (In alphabetical order)</th>
<th>Hormonal Therapy</th>
<th>Targeted Therapy</th>
<th>Radiation Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Platinum-Sensitive Disease</strong>(^b,c)</td>
<td>Carboplatin(^1)</td>
<td></td>
<td>Bevacizumab(^d,e,17,18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/docetaxel(^2,3)</td>
<td></td>
<td>Olaparib(^9,19,20)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/gemcitabine(^4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/gemcitabine/bevacizumab(^d,e) (category 2B)(^4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/liposomal doxorubicin(^5)  (category 1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/paclitaxel (category 1)(^6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carboplatin/paclitaxel (weekly)(^7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cisplatin(^8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cisplatin/gemcitabine(^8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platinum-Resistant Disease</strong></td>
<td>Docetaxel(^9)</td>
<td></td>
<td>Bevacizumab(^d,e,17,18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Etoposide, oral(^10)</td>
<td></td>
<td>Olaparib(^9,19,20)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gemcitabine(^11,12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liposomal doxorubicin(^11,12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liposomal doxorubicin/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paclitaxel (weekly)(^14)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paclitaxel (weekly)/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topotecan(^15,16)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Topotecan/bevacizumab(^d,e,13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Potentially Active Agents</strong>(^f)</td>
<td><strong>Single Agents</strong>(^21)</td>
<td>Aromatase inhibitors</td>
<td>Palliative localized radiation therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alttretamine</td>
<td>Melphalan</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Capecitabine</td>
<td>Oxaliplatin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide</td>
<td>Paclitaxel</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Doxorubicin</td>
<td>Paclitaxel, albumin bound (nab-paclitaxel)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ifosfamide</td>
<td>Pemetrexed</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Irinotecan</td>
<td>Vinorelbine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Patients who progress on two consecutive therapy regimens without evidence of clinical benefits have diminished likelihood of benefitting from additional therapy. (Griffiths RW, et al. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and Fallopian tube. Int J Gyn Ca 2011;21:58-65.) Decisions to offer clinical trials, supportive care, or additional therapy should be made on a highly individual basis.

\(^b\)In general, the panel would recommend combination regimens based on randomized trial data, especially in first relapses.

\(^c\)Platinum-based combination therapy should be considered for platinum-sensitive recurrences.

\(^d\)In patients who have not previously received bevacizumab.

\(^e\)Contraindicated for patients at increased risk of gastrointestinal perforation.

\(^f\)Many of these agents have not been tested in patients who have been treated with modern chemotherapy regimens.

\(^g\)For patients with deleterious germline BRCA-mutated (as detected by an FDA-approved test or other validated test performed in a CLIA-approved facility) advanced ovarian cancer who have been treated with three or more lines of chemotherapy.\(^20\)

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Malignant Germ Cell Tumors

**Initial surgery**
- **Fertility desired**
  - Fertility-sparing surgery and comprehensive staging (See OV-A)
  - Complete staging surgery (See OV-A)
- **Fertility not desired**
  - Consider observation (category 2B) (See LCOH-B)

**Prior surgery**
- **Incompletely surgically staged** (See OV-A)
  - Dysgerminoma or grade 1 immature teratoma
    - Positive imaging and positive tumor markers
      - Fertility desired, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery (See OV-A)
      - Consider observation (category 2B) (See LCOH-B)
    - Negative imaging and positive tumor markers
      - Fertility desired, then fertility-sparing surgery and comprehensive staging; fertility not desired, then completion staging surgery with possible tumor reductive surgery (See OV-A) or Chemotherapy (See LCOH-3)
    - Negative imaging and negative tumor markers
      - See Treatment (LCOH-3)
- **Completely staged** (See OV-A)
  - Embryonal, endodermal sinus tumor (yolk sac tumor), grade 2–3 immature teratoma, or mixed histology
    - Positive imaging and positive tumor markers
      - See Treatment (LCOH-3)
    - Negative imaging and positive tumor markers
      - Negative imaging and negative tumor markers

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Surgical principles for pediatric/young adult patients may differ from those for adult patients. See Principles of Surgery (OV-A).

Standard recommendation includes a patient evaluation by a gynecologic oncologist.
**CLINICAL PRESENTATION**

- **Stage I**
  - Dysgerminoma\(^d\)
  - or
  - Stage I, grade I Immature teratoma\(^d\)

- Any stage Embryonal tumor\(^d\)
  - or
  - Any stage Endodermal sinus tumor (yolk sac tumor)\(^d\)
  - or
  - Stage II-IV Dysgerminoma
  - or
  - Stage I, grade 2 or 3 or Stage II-IV Immature teratoma

---

**TREATMENT**

- **Stage I**
  - Dysgerminoma\(^d\)
  - or
  - Stage I, grade I Immature teratoma\(^d\)
  - Observe
  - **See Surveillance for Germ Cell and Sex-Cord Stromal Tumors (LCOH-B)**

- Any stage Embryonal tumor\(^d\)
  - or
  - Any stage Endodermal sinus tumor (yolk sac tumor)\(^d\)
  - or
  - Stage II-IV Dysgerminoma
  - or
  - Stage I, grade 2 or 3 or Stage II-IV Immature teratoma
  - Chemotherapy\(^f\)

- Residual tumor on radiographic imaging; markers normal\(^e\)
  - Consider surgical resection or Observe
  - **See LCOH-B**

- Persistently elevated markers\(^e\) with definitive residual disease
  - TIP (paclitaxel/ifosfamide/cisplatin)
  - or
  - High-dose chemotherapy (strongly recommend referral to tertiary care center for potentially curative regimen)

---

**MONITORING/FOLLOW-UP**

- Abnormal markers, definitive recurrent disease
  - Observe
  - **See LCOH-B**

- Necrotic tissue
  - Benign teratoma
  - CT or other imaging as clinically indicated
  - Residual malignancy
  - Consider additional platinum-based chemotherapy
  - **See LCOH-B**

---

**RECURRENT/PERSISTENT DISEASE**

- Complete clinical response
  - Consider additional chemotherapy\(^f\)
  - (category 2B)
  - or
  - High-dose chemotherapy
  - (category 2B)

- Incomplete clinical response
  - See LCOH-C

---

\(^d\)Pediatric/adolescent patients with the following clinical presentations may consider observation or chemotherapy as treatment options: stage IA, IB dysgerminoma; stage IA, grade 1 immature teratoma; stage IA embryonal tumors; or stage IA yolk sac tumors.

\(^e\)See LCOH-1 for markers.

\(^f\)See Acceptable Primary and Recurrence Therapies (LCOH-C).

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Clinical Presentation

Malignant sex cord-stromal tumors

- Stage IA/IC: Desires fertility
  - Fertility-sparing surgery with complete staging

- All others
  - Complete staging

Treatment

Stage I

- Low risk
  - Observe
    - See LCOH-B

- High risk
  - Observe (category 2B)
    - See LCOH-B
  - Consider platinum-based chemotherapy (category 2B)
    - Clinical trial
    - Consider secondary cytoreductive surgery or Recurrence therapy

Stage II-IV

- Platinum-based chemotherapy (category 2B)
  - Clinical relapse

- RT for limited disease (category 2B)

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See Sex Cord-Stromal Tumors - WHO Histologic Classification (LCOH-A).
See Acceptable Primary and Recurrence Therapies (LCOH-C).
Lymphadenectomy may be omitted.
See Principles of Surgery (OV-A).
Inhibin levels can be followed if initially elevated for granulosa cell tumors (category 2B).
Malignant germ cell regimens (See LCOH-C) or paclitaxel/carboplatin regimens are preferred.
Carcinosarcoma (Malignant Mixed Müllerian Tumors [MMMTs]) of the ovary

<table>
<thead>
<tr>
<th>CLINICAL PRESENTATION</th>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete surgical staging(^h)</td>
<td>Stage I-IV or Recurrence</td>
</tr>
</tbody>
</table>

\(^h\)See Principles of Surgery (OV-A).

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CLINICAL PRESENTATION

Diagnosis of LMP tumor with institutional pathology review

- Previous surgical staging was comprehensive\(^h\)
  - No invasive implants → Observe
  - Invasive implants
    - Observe or Consider treatment as epithelial ovarian cancer\(^i\) (category 2B) (See OV-2)

- Incomplete surgical staging\(^h\)
  - See LCOH-7

\(^h\)See Principles of Surgery (OV-A).
\(^i\)Standard recommendation includes a patient evaluation by a gynecologic oncologist.
\(^i\)Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CLINICAL PRESENTATION

Diagnosis of LMP tumor with institutional pathology review

Residual disease remaining after first procedure

If no desire for fertility

No residual disease remaining after first procedure

Fertility desired

No invasive implants or Unknown

Invasive implants at previous surgery

PRIMARY TREATMENT

No invasive implants or Unknown

Fertility-sparing surgery and comprehensive surgical staging, (category 2B for staging) if not previously done

Fertility-sparing surgery and comprehensive surgical staging, (category 2B for staging) if not previously done

Observe or Consider treatment as epithelial ovarian cancer (category 2B) (See OV-2)

Observe or Completion surgery

Observe or Consider treatment as epithelial ovarian cancer (category 2B) (See OV-2)

Observe or Completion surgery

Invasive implants at previous surgery

Observe

See Monitoring/ Follow-up (LCOH-8)

hSee Principles of Surgery (OV-A).

kStandard recommendation includes a patient evaluation by a gynecologic oncologist.

lChemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).

mObservation is a reasonable option regardless of whether fertility is desired.

nFor pathologically proven LMP, lymph node evaluation may be considered on a case-by-case basis.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
MONITORING/FOLLOW-UP

- Visits every 3–6 mo for up to 5 y, then annually
- Physical exam including pelvic exam
- CA-125° or other tumor markers every visit if initially elevated
- After completion of childbearing in patients who underwent USO, consider completion surgery (category 2B)
- CBC, chemistry profile as indicated
- Ultrasound as indicated for patients with fertility-sparing surgery

Clinical relapse → Surgical evaluation + debulking if appropriate

RECURRENT DISEASE

Noninvasive disease → Observe

Invasive implants of low malignant potential → See Primary Treatment (LCOH-7)

Invasive carcinoma (low or high grade) → Treatment as epithelial ovarian cancer\(^1\) (category 2B for low grade) (See OV-3)

RECURRENCE THERAPY

\(^1\)Chemotherapy (IV or IP) has not been shown to be beneficial in ovarian low malignant potential tumors (borderline epithelial ovarian tumors).

\(^o\)There are data regarding the utility of CA-125 for monitoring of ovarian cancer after completion of primary therapy. See The Society of Gynecologic Oncology (SGO) position statement and Discussion.
### SEX CORD-STROMAL TUMORS - WHO HISTOLOGIC CLASSIFICATION\(^1\)

- Sex cord-stromal tumors are a heterogenous group of very rare tumors from benign to aggressive, and each histology has a range of often well differentiated to undifferentiated. Therefore, it should be determined whether a patient has a malignant or benign sex cord-stromal tumor.
- Treatment decisions and the decision whether to preserve fertility must be individualized based on the patient’s specific tumor features.

<table>
<thead>
<tr>
<th>WHO Histologic Classification</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Granulosa cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>Malignant</td>
</tr>
<tr>
<td>Juvenile</td>
<td>Malignant</td>
</tr>
<tr>
<td><strong>Thecoma</strong></td>
<td></td>
</tr>
<tr>
<td>Thecomas, typical</td>
<td>Benign</td>
</tr>
<tr>
<td>Thecomas, luteinized</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Thecoma with increased mitotic figures</td>
<td>Malignant potential</td>
</tr>
<tr>
<td><strong>Fibroma</strong></td>
<td></td>
</tr>
<tr>
<td>Cellular fibroma</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Cellular fibroma with increased mitotic figures</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Fibrosarcoma</td>
<td>Malignant</td>
</tr>
<tr>
<td>Stromal tumor with minor sex cord elements</td>
<td>Benign</td>
</tr>
<tr>
<td>Sclerosing stromal tumor</td>
<td>Benign</td>
</tr>
<tr>
<td>Signet ring stromal tumors</td>
<td>Benign</td>
</tr>
<tr>
<td>Unclassified</td>
<td>Malignant potential</td>
</tr>
<tr>
<td><strong>Sertoli-Leydig cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Intermediate differentiation</td>
<td>Malignant</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>Malignant</td>
</tr>
<tr>
<td>Sertoli-Leydig tumors with heterologous elements</td>
<td>Malignant</td>
</tr>
<tr>
<td><strong>Sertoli cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td>Leydig cell tumors</td>
<td>Malignant potential</td>
</tr>
<tr>
<td>Stromal-Leydig cell tumors</td>
<td>Benign</td>
</tr>
<tr>
<td><strong>Sex cord tumors with annular tubules (SCTAT)</strong></td>
<td>Malignant</td>
</tr>
<tr>
<td>Microscopic SCTAT associated with Peutz-Jeghers syndrome</td>
<td>Benign</td>
</tr>
<tr>
<td>Gynandroblastoma</td>
<td>Malignant/Malignant potential</td>
</tr>
<tr>
<td>Unclassified sex cord stromal tumors</td>
<td>Malignant potential</td>
</tr>
<tr>
<td><strong>Steroid cell tumors</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Malignant</td>
</tr>
</tbody>
</table>

\(^1\)Adapted from Tavassoei FA, Devilee P (Eds): WHO Classification of Tumours, Pathology and Genetics: Tumours of the Breast and Female Genital Organs. IARC, Lyon, 2003.
### Surveillance for Germ Cell and Sex Cord-Stromal Tumors

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---


<table>
<thead>
<tr>
<th>Physical Exam</th>
<th>1-2</th>
<th>2-3</th>
<th>3-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Yearly</td>
<td>Yearly</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Serum tumor markers**</th>
<th>1-2</th>
<th>2-3</th>
<th>3-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germ cell tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Not indicated</td>
<td>Not indicated</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Every 2-4 mo</td>
<td>Every 2-4 mo</td>
<td>Every 6 mo</td>
<td>Every 6 mo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Radiographic imaging*</th>
<th>1-2</th>
<th>2-3</th>
<th>3-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germ cell tumors</td>
<td>As clinically indicated unless markers normal at initial presentation</td>
<td>As clinically indicated unless markers normal at initial presentation</td>
<td>As clinically indicated</td>
<td>As clinically indicated</td>
</tr>
<tr>
<td>Sex cord-stromal tumors</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
<td>Insufficient data to support routine use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recurrence suspected</th>
<th>1-2</th>
<th>2-3</th>
<th>3-5</th>
<th>&gt;5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
<td>CT scan and tumor markers **</td>
</tr>
</tbody>
</table>

---

**LCOH-B**
### ACCEPTABLE PRIMARY AND RECURRENCE THERAPIES

#### ACCEPTABLE PRIMARY THERAPIES

**Malignant Germ Cell Tumors**

- **BEP (bleomycin, etoposide, cisplatin)**\(^1\)
  - Bleomycin 30 units per week, etoposide 100 mg/m\(^2\) daily for days 1–5, cisplatin 20 mg/m\(^2\) daily for days 1–5
  - Repeat every 21 days for 3 cycles for good risk (category 2B), or 4 cycles for poor risk.

- Etoposide/carboplatin
  - For select patients with stage IB-III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used.
  - Carboplatin 400 mg/m\(^2\) on day 1 plus etoposide 120 mg/m\(^2\) on days 1, 2, and 3 every 4 weeks for 3 courses.

#### ACCEPTABLE RECURRENCE THERAPIES

**Malignant Germ Cell Tumors**\(^2\)

- High-dose chemotherapy\(^2,3\)
- Cisplatin/etoposide
- Docetaxel
- Docetaxel/carboplatin
- Paclitaxel
- Paclitaxel/ifosfamide
- Paclitaxel/carboplatin
- Paclitaxel/gemcitabine
- VIP (etoposide, ifosfamide, cisplatin)
- VeIP (vinblastine, ifosfamide, cisplatin)
- VAC (vincristine, dactinomycin, cyclophosphamide)
- TIP (paclitaxel, ifosfamide, cisplatin)
- Radiation therapy
- Supportive care only

**Malignant Sex Cord-Stromal Tumors**\(^4\)

- Aromatase inhibitors (anastrozole, letrozole)
- Bevacizumab may be considered for granulosa cell tumors
- Leuprolide may be used as hormonal therapy for granulosa cell tumors
- Docetaxel
- Paclitaxel
- Paclitaxel/ifosfamide
- Paclitaxel/carboplatin
- Tamoxifen
- VAC
- Radiation therapy
- Supportive care only

---

1. Recommend pulmonary function test if considering bleomycin.
2. Patients with potentially curable recurrent germ cell disease should be referred to a tertiary care institution for potentially curative therapy.
3. High-dose chemotherapy regimens vary among institutions.

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Staging**

*American Joint Committee on Cancer (AJCC)*

TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)

**Primary Tumor (T)**

<table>
<thead>
<tr>
<th>TNM</th>
<th>FIGO</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>Tumor limited to ovaries (one or both)</td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>IA</td>
<td>Tumor limited to one ovary; capsule intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T1b</td>
<td>IB</td>
<td>Tumor limited to both ovaries; capsules intact, no tumor on ovarian surface. No malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T1c</td>
<td>IC</td>
<td>Tumor limited to one or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T2</td>
<td>II</td>
<td>Tumor involves one or both ovaries with pelvic extension</td>
</tr>
<tr>
<td>T2a</td>
<td>IIA</td>
<td>Extension and/or implants on uterus and/or tube(s). No malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T2b</td>
<td>IIB</td>
<td>Extension to and/or implants on other pelvic tissues. No malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T2c</td>
<td>IIC</td>
<td>Pelvic extension and/or implants (T2a or T2b) with malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T3</td>
<td>III</td>
<td>Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis</td>
</tr>
<tr>
<td>T3a</td>
<td>IIIA</td>
<td>Microscopic peritoneal metastasis beyond pelvis (no macroscopic tumor)</td>
</tr>
<tr>
<td>T3b</td>
<td>IIIB</td>
<td>Macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T3c</td>
<td>IIIC</td>
<td>Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis</td>
</tr>
</tbody>
</table>

**Regional Lymph Nodes (N)**

| NX  | Regional lymph nodes cannot be assessed |
| N0  | No regional lymph node metastasis |
| N1  | IIIC | Regional lymph node metastasis |

**Distant Metastasis (M)**

| M0  | No distant metastasis |
| M1  | IV   | Distant metastasis (excludes peritoneal metastasis) |

Note: Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.

*An update to the FIGO staging guidelines is available. [See FIGO Guidelines (ST-5)].*
### Staging*

*Table 1 (Continued)*  
**American Joint Committee on Cancer (AJCC)**  
**TNM and FIGO Staging System for Ovarian and Primary Peritoneal Cancer (7th ed., 2010)**

<table>
<thead>
<tr>
<th>Stage Grouping</th>
<th>TNM</th>
<th>FIGO Staging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 1</td>
<td>T1</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1a</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T1b</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IC</td>
<td>T1c</td>
<td>N0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T2a</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2b</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIC</td>
<td>T2c</td>
<td>N0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T3</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T3a</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T3b</td>
<td>N0</td>
</tr>
<tr>
<td>Stage IIIC</td>
<td>T3c</td>
<td>N0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N1</td>
</tr>
</tbody>
</table>

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

The staging system for ovarian and primary peritoneal cancer is also used for malignant germ cell tumors, malignant sex cord-stromal tumors, and carcinosarcoma (malignant mixed Müllerian tumors).

---

An update to the FIGO staging guidelines is available. See FIGO Guidelines (ST-5).
**Table 2**

American Joint Committee on Cancer (AJCC) 
TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>TNM FIGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Tis**</td>
<td>Carcinoma in situ (limited to tubal mucosa)</td>
</tr>
<tr>
<td>T1 I</td>
<td>Tumor limited to the Fallopian tube(s)</td>
</tr>
<tr>
<td>T1a IA</td>
<td>Tumor limited to one tube, without penetrating the serosal surface; no ascites</td>
</tr>
<tr>
<td>T1b IB</td>
<td>Tumor limited to both tubes, without penetrating the serosal surface; no ascites</td>
</tr>
<tr>
<td>T1c IC</td>
<td>Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T2 II</td>
<td>Tumor involves one or both Fallopian tubes with pelvic extension</td>
</tr>
<tr>
<td>T2a IIA</td>
<td>Extension and/or metastasis to the uterus and/or ovaries</td>
</tr>
<tr>
<td>T2b IIB</td>
<td>Extension to other pelvic structures</td>
</tr>
<tr>
<td>T2c IIC</td>
<td>Pelvic extension with malignant cells in ascites or peritoneal washings</td>
</tr>
<tr>
<td>T3 III</td>
<td>Tumor involves one or both Fallopian tubes, with peritoneal implants outside the pelvis</td>
</tr>
<tr>
<td>T3a IIA</td>
<td>Microscopic peritoneal metastasis outside the pelvis</td>
</tr>
<tr>
<td>T3b IIB</td>
<td>Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T3c IIC</td>
<td>Peritoneal metastasis outside the pelvis and more than 2 cm in diameter</td>
</tr>
</tbody>
</table>

**Regional Lymph Nodes (N)**

| N0               | No regional lymph node metastasis |
| N1 IIC           | Regional lymph node metastasis |

**Distant Metastasis (M)**

| M0               | No distant metastasis |
| M1 IV            | Distant metastasis (excludes metastasis within the peritoneal cavity) |

**Note:** FIGO no longer includes stage 0 (Tis)

**Note:** Liver capsule metastasis is T3/stage III; liver parenchymal metastasis, M1/stage IV. Pleural effusion must have positive cytology for M1/stage IV.

*An update to the FIGO staging guidelines is available. [See FIGO Guidelines (ST-5)].*
### Table 2 (Continued)
**American Joint Committee on Cancer (AJCC)**
**TNM and FIGO Staging System for Fallopian Tube Cancer (7th ed., 2010)**

**Stage Grouping**

<table>
<thead>
<tr>
<th>Stage</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>0**</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>1</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IA</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IB</td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IC</td>
<td>T1c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIA</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIB</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIC</td>
<td>T2c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIIA</td>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIIB</td>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IIIC</td>
<td>T3c</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

**Note:** FIGO no longer includes stage 0 (Tis)

Note: For histologic grade and histopathologic type, see AJCC Staging Manual.

An update to the FIGO staging guidelines is available. [See FIGO Guidelines (ST-5)](http://www.cancerstaging.net).

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.cancerstaging.net](http://www.cancerstaging.net).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
### International Federation of Gynecology and Obstetrics (FIGO)

**FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum**

<table>
<thead>
<tr>
<th>FIGO</th>
<th>TNM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>T1</td>
<td>Tumor confined to ovaries or Fallopian tube(s)</td>
</tr>
<tr>
<td>IA</td>
<td>T1a</td>
<td>Tumor limited to 1 ovary (capsule intact) or Fallopian tube; no tumor on ovarian or Fallopian tube surface; no malignant cells in the ascites or peritoneal washings</td>
</tr>
<tr>
<td>IB</td>
<td>T1b</td>
<td>Tumor limited to both ovaries (capsules intact) or Fallopian tubes; no tumor on ovarian or Fallopian tube surface; no malignant cells in the ascites or peritoneal washings</td>
</tr>
<tr>
<td>IC</td>
<td></td>
<td>Tumor limited to 1 or both ovaries or Fallopian tubes, with any of the following:</td>
</tr>
<tr>
<td>IC1</td>
<td>T1c1</td>
<td>Surgical spill</td>
</tr>
<tr>
<td>IC2</td>
<td>T1c2</td>
<td>Capsule ruptured before surgery or tumor on ovarian or Fallopian tube surface</td>
</tr>
<tr>
<td>IC3</td>
<td>T1c3</td>
<td>Malignant cells in the ascites or peritoneal washings</td>
</tr>
<tr>
<td>II</td>
<td>T2</td>
<td>Tumor involves 1 or both ovaries or Fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer</td>
</tr>
<tr>
<td>IIA</td>
<td>T2a</td>
<td>Extension and/or implants on uterus and/or Fallopian tubes and/or ovaries</td>
</tr>
<tr>
<td>IIB</td>
<td>T2b</td>
<td>Extension to other pelvic intraperitoneal tissues</td>
</tr>
<tr>
<td>III</td>
<td>T1/T2-N1</td>
<td>Tumor involves 1 or both ovaries or Fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes</td>
</tr>
<tr>
<td>IIIA1</td>
<td></td>
<td>Positive retroperitoneal lymph nodes only (cytologically or histologically proven):</td>
</tr>
<tr>
<td>IIIA1(i)</td>
<td></td>
<td>Metastasis up to 10 mm in greatest dimension</td>
</tr>
<tr>
<td>IIIA1(ii)</td>
<td></td>
<td>Metastasis more than 10 mm in greatest dimension</td>
</tr>
<tr>
<td>IIIA2</td>
<td>T3a2-N0/N1</td>
<td>Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes</td>
</tr>
<tr>
<td>IIIB</td>
<td>T3b-N0/N1</td>
<td>Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes</td>
</tr>
<tr>
<td>IIIC</td>
<td>T3c-N0/N1</td>
<td>Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)</td>
</tr>
<tr>
<td>IV</td>
<td>Any T, any N, M1</td>
<td>Distant metastasis excluding peritoneal metastases</td>
</tr>
<tr>
<td>IVA</td>
<td></td>
<td>Pleural effusion with positive cytology</td>
</tr>
<tr>
<td>IVB</td>
<td></td>
<td>Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)</td>
</tr>
</tbody>
</table>

Discussion

NCCN Categories of Evidence and Consensus

**Category 1:** Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

- Overview ............................................................... MS-3
- Screening ............................................................... MS-4
- Staging ............................................................... MS-5
- Caveat ............................................................... MS-5
- Literature Search Criteria and Guidelines Update Methodology ...... 6
- Epithelial Ovarian Cancer ............................................................. MS-6
- Recommended Workup ............................................................. MS-6
- Undiagnosed Pelvic Mass ............................................................. MS-6
- Prior Diagnosis of Malignancy ............................................................. MS-7
- Primary Treatment ............................................................. MS-8
- Risk-Reducing Surgery ............................................................. MS-8
- Cytoreductive Surgery ............................................................. MS-9
- Neoadjuvant Chemotherapy ............................................................. MS-10
- Incomplete Surgery and/or Staging ............................................................. MS-10
- Chemotherapy ............................................................. MS-11
- Anti-Angiogenesis Agents ............................................................. MS-13
- Number of Chemotherapy Cycles and Agents ............................................................. MS-14
- Drug Reactions ............................................................. MS-15
- Radiation Therapy ............................................................. MS-15
- Recommendations After Primary Treatment ............................................................. MS-15
- Follow-up Recommendations ............................................................. MS-16
- Management of an Increasing CA-125 Level ............................................................. MS-17
- Recurrent Disease ............................................................. MS-17
- Acceptable Recurrence Modalities ............................................................. MS-18
- Less Common Ovarian Histopathologies ............................................................. MS-21
- Recommended Workup ............................................................. MS-21
- Malignant Germ Cell Tumors ............................................................. MS-21
- Treatment ............................................................. MS-21
- Residual or Recurrent Disease ............................................................. MS-23
- Malignant Sex Cord-Stromal Tumors ............................................................. MS-23
Carcinosarcomas (Malignant Mixed Müllerian Tumors) ........ MS-24

Ovarian Low Malignant Potential Tumors (Borderline Epithelial Ovarian Tumors) ................................................................. MS-24

Diagnosis .................................................................................... MS-24

Treatment .................................................................................. MS-25

Follow-up .................................................................................. MS-25

Relapse ....................................................................................... MS-25

Recommended Readings ............................................................ MS-26

References .................................................................................. MS-27
Overview

Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%); however, other less common pathologic subtypes may occur. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer were originally published 20 years ago and have been subsequently updated at least once every year. These NCCN Guidelines® discuss epithelial ovarian cancer and less common histopathologies, including ovarian low malignant potential (LMP) tumor, malignant germ cell neoplasms, carcinosarcomas (malignant mixed Müllerian tumors [MMMTs] of the ovary), and malignant sex cord-stromal tumors. The NCCN Guidelines also discuss Fallopian tube cancer and primary peritoneal cancer, which are less common neoplasms that are managed in a similar manner to epithelial ovarian cancer. However, the less common histologies of ovarian cancer are managed differently.

These NCCN Guidelines also include sections on Principles of Chemotherapy (including Acceptable Recurrence Therapies), Principles of Surgery, and Management of Drug Reactions. The Summary of the Guidelines Updates section in the algorithm briefly describes the new changes for 2015. The Principles of Surgery were extensively revised for 2015 and now include 2 new sections: Operative Reports and a Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol (see the NCCN Guidelines for Ovarian Cancer).

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. In 2015, it is estimated that 21,290 new diagnoses and 14,180 deaths from this neoplasm will occur in the United States; less than 40% of women with ovarian cancer are cured. The incidence of ovarian cancer increases with age and is most prevalent in the sixth and seventh decades of life. The median age at the time of diagnosis is 63 years, and more than 70% of patients present with advanced disease.

Epidemiologic studies have identified risk factors in the etiology of ovarian cancer. A 30% to 60% decreased risk for cancer is associated with younger age at pregnancy and first birth (≤25 years), the use of oral contraceptives, and/or breastfeeding. Conversely, nulliparity or older age (>35 years) at pregnancy and first birth confers an increased risk for ovarian cancer. Data suggest that hormone therapy and pelvic inflammatory disease may increase the risk for ovarian cancer. The risk for ovarian LMP tumors (also known as borderline epithelial ovarian tumors) may be increased after ovarian stimulation for in vitro fertilization. Obesity does not appear to be associated with the most aggressive types of ovarian cancer. Environmental factors have been investigated, but so far they have not been conclusively associated with the development of this neoplasm.

Family history (primarily patients having 2 or more first-degree relatives with ovarian cancer)—including linkage with BRCA1 and BRCA2 genotypes (hereditary breast and ovarian cancer [HBOC] syndrome) or families affected by Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC] syndrome)—is associated with early-onset disease. However, these patients account for only 15% of all women who have ovarian cancer. In women at high risk (with either BRCA1 or BRCA2 mutations), prophylactic bilateral salpingo-oophorectomy (BSO) is associated with a reduced risk for breast, ovarian, Fallopian tube, and primary peritoneal cancers (see Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol (BRCA/HBOC syndrome) in the NCCN Guidelines for Ovarian Cancer, Cytoreductive Surgery in this Discussion, and Risk...
Reduction Surgery in the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian). However, there is a residual risk for primary peritoneal cancer after prophylactic BSO in these women at high risk for cancer. Occult ovarian cancer is sometimes found after prophylactic salpingo-oophorectomy, thus emphasizing the need for careful pathologic review of the ovaries and tubes (see Risk-Reducing Salpingo-Oophorectomy [RRSO] Protocol [BRCA/HBOC syndrome] in the NCCN Guidelines for Ovarian Cancer). The risks of surgery include injury to the bowel, bladder, ureter, and vessels. Recently, it has been suggested that the Fallopian tube may be the origin of serous ovarian and primary peritoneal cancers, including serous intraepithelial carcinoma of the Fallopian tube (also known as serous tubal intraepithelial carcinoma [STIC]). A referral to a gynecologic oncologist/comprehensive cancer center is recommended for management of occult STIC.

Screening

Because of the location of the ovaries and the biology of most epithelial cancers, it has been difficult to diagnose ovarian cancer at an earlier, more curable stage. However, evaluations of patients with newly diagnosed ovarian cancer have resulted in consensus guidelines for ovarian cancer symptoms, which may enable earlier identification of patients who may be at an increased risk of having developed early-stage ovarian cancer. Symptoms suggestive of ovarian cancer include: bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary symptoms (urgency or frequency), especially if these symptoms are new and frequent (>12 days/month). Physicians evaluating women with this constellation of symptoms must be cognizant of the possibility that ovarian pathology may be causing these symptoms. However, some evidence suggests that the screening test using these symptoms is not as sensitive or specific as necessary, especially in those with early-stage disease.

An ongoing trial is assessing screening for ovarian cancer (UK Collaborative Trial of Ovarian Cancer Screening [UKCTOCS]) using multimodality screening with ultrasound and cancer antigen 125 (CA-125) versus either ultrasound alone or no screening. Preliminary results suggest that multimodality screening is more effective at detecting early-stage cancer. However, a large randomized trial in more than 78,000 women (the Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer trial) in the United States found that screening with transvaginal ultrasonography and CA-125 did not decrease mortality from ovarian cancer. In addition, false-positive results led to serious complications in some women (n = 163) in the PLCO trial. Another study—comparing 1) CA-125 alone; 2) ultrasound with CA-125; or 3) ultrasound alone—found that CA-125 did not increase the detection of cancer over ultrasound alone and that ultrasound was superior to CA-125 alone.

Randomized data do not yet support routine screening for ovarian cancer in the general population, and routine screening is not currently recommended by any professional society. Some physicians follow women with high-risk factors (e.g., those with BRCA mutations, those with a family history) using CA-125 monitoring and endovaginal ultrasound; however, prospective validation of these tests remains elusive. An intriguing study suggests that ovarian cancer is associated with unique odors that can be detected.

A screening trial assessed an algorithm that used age and longitudinal changes in CA-125 levels to determine whether women at average risk would develop ovarian cancer (Risk of Ovarian Cancer Algorithm [ROCA]); women deemed at risk were referred for transvaginal
sonography. However, until data from larger randomized controlled trials are published (e.g., UKCTOCS), there is not enough evidence to support this screening approach for women at low risk for ovarian cancer. Some feel that the ROCA may be useful for women at high risk such as those with BRCA mutations.

The Society of Gynecologic Oncology (SGO), the FDA, and the Mayo Clinic have stated that the OVA1 test should not be used as a screening tool to detect ovarian cancer. The OVA1 test uses 5 markers (including transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125) to assess who should undergo surgery by an experienced gynecologic oncologist and who can have surgery in the community. Based on data documenting an increased survival, NCCN Panel Members recommend that all patients should undergo surgery by an experienced gynecologic oncologist (category 1). NCCN Panel Members believe that the OvaSure screening test should not be used to detect ovarian cancer. The OvaSure test uses 6 biomarkers, including leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and CA-125. Data show that several markers (including CA-125, HE4, mesothelin, B7-H4, decoy receptor 3 [DcR3], and spondin-2) do not increase early enough to be useful in detecting early-stage ovarian cancer.

Staging

The NCCN Guidelines for Ovarian Cancer reflect the importance of stage and grade of disease on prognosis and treatment recommendations. Ovarian cancer is classified primarily as stages I to IV using the FIGO (International Federation of Gynecology and Obstetrics) and AJCC staging systems (see Table 1 and other staging tables in the NCCN Guidelines for Ovarian Cancer). Most patients present with stage III disease. Pathologic grading is an important prognostic factor and is used in the selection of therapy, primarily for early-stage disease. Grading is labeled as 1, 2, or 3. Some pathologists recommend that serous ovarian cancer be graded as either low grade (most grade 1 serous tumors) or high grade (most grade 2 or 3 serous tumors). Except for those women with stage I, grade 1 tumors (in whom survival is greater than 95% after comprehensive laparotomy), patients in all other stages of ovarian cancer should be encouraged to enter clinical trials for both primary and recurrence therapy. Primary peritoneal adenocarcinoma is staged using the ovarian cancer staging system (see Table 1 in the NCCN Guidelines for Ovarian Cancer). Fallopian tube carcinomas are staged using a separate FIGO and AJCC staging system, although this will change with the new FIGO staging guidelines (see Table 2 in the NCCN Guidelines for Ovarian Cancer).

FIGO recently updated the staging for ovarian, Fallopian tube, and peritoneal cancer; their new staging system has been approved by the AJCC (see Staging in the NCCN Guidelines for Ovarian Cancer). For example, in the new staging guidelines, old stages IC, IIIA, and IV are now subdivided; the old stage IIC has been eliminated (https://www.sgo.org/wp-content/uploads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf). However, these changes will be included in the next edition of the AJCC Cancer Staging Manual (8th edition), which will be published in mid-2016 and will be effective for all cancer cases recorded on or after January 1, 2017. The 2013 protocols from the College of American Pathologists (CAP) do not include the new FIGO staging system (see Protocol for the Examination of Specimens from Patients With Carcinoma of the Ovary on the CAP website).

Caveat

By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment...
or individualization of treatments. Exceptions to the rule were discussed among panel members during the process of developing these guidelines. A 5% rule (omitting clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines.

**Literature Search Criteria and Guidelines Update Methodology**

Prior to the update of this version of the NCCN Guidelines for Ovarian Cancer, an electronic search of the PubMed database was performed to obtain key literature in ovarian cancer published between October 1, 2013 and September 1, 2014 using the following search term: ovarian cancer. The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature. The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 120 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion. The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN webpage.

**Epithelial Ovarian Cancer**

**Recommended Workup**

The NCCN Guidelines for Epithelial Ovarian Cancer begin with the management of an undiagnosed pelvic mass or a prior diagnosis of a malignant epithelial ovarian tumor. Many patients with this diagnosis come to NCCN Member Institutions after having had previous surgery. The NCCN Guidelines recommend symptom management and best supportive care for all patients; patients should be referred for palliative care assessment if appropriate (see the NCCN Guidelines for Palliative Care, available at NCCN.org). The NCCN Guidelines also recommend that all patients with ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer be referred for genetic risk evaluation (see the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, available at NCCN.org). However, primary treatment should not be delayed for risk evaluation.

**Undiagnosed Pelvic Mass**

The primary workup should include an ultrasound and/or abdominal/pelvic CT/MRI scan (after an abdominal/pelvic examination) and appropriate laboratory studies for a patient with a suspicious pelvic mass (detected on abdominal/pelvic exam) and/or ascites, abdominal distention, and/or symptoms (ie, bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, urinary symptoms) without other obvious sources of malignancy (see *Workup* in the NCCN Guidelines for Epithelial Ovarian Cancer). Tumor markers (including CA-125, inhibin, alpha-fetoprotein [AFP], and beta–human chorionic gonadotropin [beta-HCG]) can be measured if clinically indicated to assess for less common ovarian histopathologies (LCOH) and pregnancy (see *Less Common Ovarian Histopathologies* in this Discussion and the NCCN Guidelines for Less Common Ovarian Cancer).
Histopathologies).\textsuperscript{113-115} For example, AFP levels should be considered to assess for germ cell tumors in women younger than 35 years with a pelvic mass.\textsuperscript{113-115} Ultrasound is typically used for initial evaluation; however, CT is useful to assess for metastases.\textsuperscript{107} MRI may be useful for determining malignant potential if ultrasound is not reliable.\textsuperscript{111,112} PET/CT scan may be useful for indeterminate lesions.\textsuperscript{116-118}

If possible, fine-needle aspiration (FNA) should be avoided for diagnosis of ovarian cancer in patients with presumed early-stage disease to prevent rupturing the cyst and spilling malignant cells into the peritoneal cavity; however, FNA may be necessary in patients with bulky disease who are not surgical candidates.\textsuperscript{119,120} Other cancers that should be ruled out include bowel, uterine, and pancreatic cancers or lymphoma;\textsuperscript{121,122} benign ovarian and non-ovarian conditions also need to be ruled out (eg, serous cystadenoma).\textsuperscript{123}

It has been suggested that specific biomarkers (serum HE4 and CA-125) along with an algorithm (Risk of Ovarian Malignancy Algorithm [ROMA]) may be useful for determining whether a pelvic mass is malignant or benign.\textsuperscript{124} The FDA has approved the use of HE4 and CA-125 for estimating the risk for ovarian cancer in women with a pelvic mass. Currently, the NCCN Panel does not recommend the use of these biomarkers for determining the status of an undiagnosed pelvic mass.\textsuperscript{125-127} Both primary peritoneal and Fallopian tube cancers are usually diagnosed postoperatively (if there is no major involvement of the ovary) or preoperatively (if there is a biopsy and the patient has already had a bilateral oophorectomy). Primary peritoneal and Fallopian tube cancers are treated in the same manner as epithelial ovarian cancer. Although there is no direct evidence that chest imaging is necessary, panel members felt that it should be part of the overall evaluation of a patient before surgical staging. Additional diagnostic studies, such as gastrointestinal tract evaluation, are not routinely recommended, although they could prove useful in specific clinical situations.

\textbf{Prior Diagnosis of Malignancy}

Patients are often referred to NCCN Member Institutions after having a previous diagnosis of ovarian cancer by surgery or tissue biopsy (cytopathology). Often they have had cytoreductive surgery and comprehensive staging procedures (ie, having met the standards for surgical staging of the Gynecologic Oncology Group [GOG]). However, in some instances, referral occurs after incomplete surgery and/or staging (eg, uterus and/or adnexa intact, omentum not removed, residual disease that is potentially resectable, surgical stage not completely documented). The components of surgical staging are listed in the algorithm (see \textit{Principles of Surgery} in the NCCN Guidelines for Epithelial Ovarian Cancer). Identical workup procedures are recommended for patients having undiagnosed or diagnosed pelvic masses at the time of referral.

Epithelial ovarian cancer has 4 main histologic subtypes (eg, serous, endometrioid, mucinous, clear cell); however, most patients (about 70\%) have serous histology.\textsuperscript{2,95,98,128,129} Primary treatment for these histologic subtypes does not differ; they are all treated using the recommendations for epithelial ovarian cancer (see the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{98} However, stage I clear cell carcinoma is treated using recommendations for stage I, grade 3 epithelial ovarian cancer. Recent molecular characterization of clear cell, mucinous, or low-grade tumors suggests that mutations in these histologies are different from those in higher grade tumors.\textsuperscript{40,130,131} Ovarian cancer can be divided into Types 1 and 2 based on these molecular alterations. Data suggest that serous tumors can be categorized as either low grade (most grade 1 serous tumors) or high grade (most grade 2 or 3 serous tumors).\textsuperscript{96-100,132,133} Low-grade serous
tumors are relatively resistant to standard chemotherapy regimens.\textsuperscript{98,134} At present, treatment of these histologies with alternative chemotherapy regimens or targeted agents should be performed in clinical trials, which are strongly encouraged for these subgroups.\textsuperscript{135} Pathology review at NCCN Member Institutions is recommended for all patients. The CAP protocols are a useful tool for pathology reports (see Protocol for the Examination of Specimens from Patients with Carcinoma of the Ovary on the CAP website).\textsuperscript{101} The WHO pathology manual is also a useful resource.\textsuperscript{136}

Primary Treatment

Primary treatment for presumed ovarian cancer consists of appropriate surgical staging and cytoreduction, followed in most (but not all) patients by systemic chemotherapy.\textsuperscript{83,137} Initial surgery should be a comprehensive staging laparotomy, including a total abdominal hysterectomy (TAH) and BSO (see the Principles of Surgery in the NCCN Guidelines for Ovarian Cancer).\textsuperscript{7,138,139} Based on published improved outcomes, it is recommended (category 1) that a gynecologic oncologist perform the primary surgery.\textsuperscript{84-86} For a young patient who wishes to maintain fertility, a unilateral salpingo-oophorectomy (USO) (preserving the uterus and contralateral ovary) may be adequate for select stage I tumors (stage 1A and 1C, but not stage 1B) and/or low-risk ovarian tumors (ie, early-stage, low-grade invasive tumors; ovarian LMP tumors).\textsuperscript{140-145}

Comprehensive surgical staging should still be performed to rule out occult higher-stage disease, because data show that approximately 30\% of patients undergoing complete staging surgery are upstaged.\textsuperscript{146} In select patients, minimally invasive procedures may be used for surgical staging.\textsuperscript{138,147-150} In early-stage disease, minimally invasive techniques to achieve the surgical goals may be considered in selected patients if performed by an experienced gynecologic oncologist.\textsuperscript{112,138,151,152} Surgeons tend to use an open laparotomy for patients with more widespread disease.\textsuperscript{152,153} Minimally invasive techniques may be considered for prophylactic salpingo-oophorectomy.

Two new sections were added to the Principles of Surgery for the 2015 update: Operative Reports and a Risk-Reducing Salpingo-Oophorectomy (RRSO) Protocol (BRCA/HBOC syndrome) (see the NCCN Guidelines for Epithelial Ovarian Cancer). To summarize the new operative report, the surgeon should describe the following: 1) the extent of initial disease; 2) the amount of residual disease; and 3) whether a complete or incomplete resection (including a description of the lesions) was achieved.\textsuperscript{154}

Risk-Reducing Surgery

The new RRSO protocol is recommended for patients at risk for HBOC and is described in detail in the algorithm (see the Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer, the Overview in this Discussion, and the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian).\textsuperscript{34} This protocol recommends that the Fallopian tubes should be processed by sectioning and extensively examining the fimbriated end (SEE-Fim) of the tubes and then assessed to determine whether any evidence of cancer is present.\textsuperscript{32,49} The ovaries should also be carefully sectioned, processed, and assessed.\textsuperscript{155} The CAP protocol for Fallopian tube carcinoma is a useful tool (see Protocol for the Examination of Specimens From Patients with Carcinoma of the Fallopian Tube on the CAP website).\textsuperscript{155} Note that it is controversial whether a hysterectomy should also be done after RRSO.\textsuperscript{25}
**Cytoreductive Surgery**

Cytoreductive surgery is the initial treatment recommendation for patients with clinical stage II, III, or IV disease (see Primary Treatment in the NCCN Guidelines for Epithelial Ovarian Cancer). Although cytoreductive surgery is the standard of care, this recommendation is based on retrospective data (and thus is not a category 1 recommendation). In general, the procedures outlined in the next paragraph should be part of the surgical management of patients with ovarian, Fallopian tube, or primary peritoneal cancer in an effort to fully stage patients and to achieve maximal cytoreduction to less than 1-cm residual disease or resection of all visible disease in appropriate circumstances. Surgical cytoreduction is optimal if the residual tumor nodules are less than 1 cm in maximum diameter or thickness; extensive resection of upper abdominal ovarian metastases is recommended for patients who can tolerate this surgery. In select patients, minimally invasive procedures may be used to assess whether cytoreductive surgery is feasible and to achieve cytoreduction.

A maximal effort should be made to remove all gross disease, because the more complete the debulking the better the outcomes. On entering the abdomen, aspiration of ascites or peritoneal lavage should be performed for cytologic examinations. For obvious disease beyond the ovaries, cytologic assessment of ascites and/or lavage specimens will not alter stage or management. Hysterectomy and BSO should be performed. Although total hysterectomy is recommended for most patients, a supracervical hysterectomy is appropriate in some circumstances. An encapsulated mass should be removed intact, if possible. All involved omentum should be removed. Suspicious and/or enlarged nodes should be resected, if possible. Bilateral pelvic and para-aortic lymph node dissection is recommended for those patients with tumor nodules, outside the pelvis, of 2 cm or less (presumed stage IIIB) (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer). For young patients who will abruptly enter menopause after surgery, various supportive care measures may be used to help decrease hot flashes and other symptoms.

Most patients have a hysterectomy with BSO, omentectomy, and lymphadenectomy of suspicious/enlarged nodes (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer). Some surgeons classify debulking based on the number of procedures. In patients with advanced ovarian cancer who have had complete debulking, data indicate that overall survival is increased in those who receive systematic lymphadenectomy. Patients with low-volume residual disease after surgical cytoreduction for invasive epithelial ovarian or peritoneal cancer are potential candidates for intraperitoneal (IP) therapy. Procedures that may be considered for optimal surgical cytoreduction (in all stages) include: radical pelvic dissection, bowel resection, diaphragm or other peritoneal surface stripping, splenectomy, partial hepatectomy, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy, distal pancreatectomy, or appendectomy.

For the 2015 update, the surgical guidelines now emphasize that an open laparotomy should be used for patients with suspected malignant ovarian cancer if the treatment plan involves surgical staging, primary debulking, interval debulking, or secondary cytoreduction (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer). The surgical guidelines also now state that if patients cannot be optimally debulked using minimally invasive techniques, they should be converted to an open procedure. Neoadjuvant therapy can be
considered if maximal cytoreduction cannot be achieved (see Neoadjuvant Chemotherapy in this Discussion). The RRSO protocol is used for patients at risk for HBOC and is described in detail in the algorithm; this protocol recommends that the Fallopian tubes should be processed by SEE-Fim of the tubes and then assessed to determine whether any evidence of cancer is present (see also Protocol for the Examination of Specimens From Patients With Carcinoma of the Fallopian Tube on the CAP website). The ovaries should also be carefully sectioned, processed, and assessed.

Neoadjuvant Chemotherapy

The therapeutic benefit of neoadjuvant chemotherapy followed by interval cytoreduction remains controversial (see next paragraph). It may be considered (category 1) for patients with bulky stage III to IV disease who are not surgical candidates; however, a gynecologic oncologist should make this assessment before neoadjuvant chemotherapy is administered. Standard intravenous regimens described in the algorithm may be used for neoadjuvant chemotherapy (see Principles of Chemotherapy in the NCCN Guidelines for Ovarian Cancer). Before initiation of chemotherapy, the pathologic diagnosis should be confirmed (by FNA, biopsy, or paracentesis) in this group of patients. If there are concerns about the histology, a core biopsy can be obtained; minimally invasive techniques may be used to obtain the biopsy.

Neoadjuvant therapy refers to treatment (eg, drugs, radiation, other treatment) that is given to reduce the tumor burden before cancer surgery (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). A randomized phase III trial assessed neoadjuvant chemotherapy with interval debulking surgery versus upfront primary debulking surgery in patients with extensive-stage IIIC/IV ovarian, primary peritoneal, and Fallopian tube carcinoma (sponsored by the EORTC-GCG and the NCIC-CTG). Median overall survival was equivalent in these patients (29 vs. 30 months), but patients receiving neoadjuvant chemotherapy with interval debulking surgery had fewer complications.

A major criticism of this international trial is that reported progression-free survival (PFS) and overall survival were inferior to those reported more recently in randomized studies in the United States of patients undergoing primary debulking surgery followed by postoperative intravenous chemotherapy for advanced ovarian cancer (overall survival averages about 50 months). Although the median overall survival in the international trial is 20 months lower than that reported in U.S. trials using the customary sequence of therapeutic interventions (ie, primary debulking surgery followed by chemotherapy), this difference may have been a result of selection of patients at higher risk to the international trial (which did not include patients with stage IIIB or earlier-stage cancer). Also, primary or interval debulking surgery in the international trial may have been suboptimal (ie, patients may have had >1 cm of residual disease). A recent retrospective analysis of the EORTC-NCIC trial reported that patients with stage IV disease with bulky tumors had longer survival with neoadjuvant therapy, whereas those with stage IIIC disease and less bulky tumors had longer survival with upfront surgery. In the opinion of the subcommittee for the NCCN Guidelines for Ovarian Cancer, more data will be necessary prior to recommending neoadjuvant chemotherapy in patients with potentially resectable ovarian cancer, and upfront debulking surgery remains the treatment of choice in the United States.

Incomplete Surgery and/or Staging

For patients with incomplete previous surgery and/or staging, treatment recommendations are outlined in the algorithm (see Diagnosis by Previous Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer).
Cancer). For patients with stage II to IV disease who have residual disease that is considered unresectable, consider completion surgery after 3 cycles of chemotherapy. Completion surgery after 3 cycles is preferred; however, surgery may be performed after 4 to 6 cycles based on the clinical judgment of the gynecologic oncologist. Depending on the surgical results, postoperative chemotherapy may be recommended. Tumor reductive surgery is recommended for all patients with stage II to IV disease with suspected residual disease that is potentially resectable.

**Chemotherapy**

Most patients with epithelial ovarian cancer receive postoperative systemic chemotherapy, which is also referred to as adjuvant therapy (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Observation, however, is recommended for patients with stage IA or IB, grade 1 tumors, because survival is greater than 90% for this group with surgical treatment alone.\(^{191-193}\) If observation (without the addition of chemotherapy) is considered for stage IA or IB grade 2 tumors, a surgical staging procedure is recommended for all patients. Recommendations regarding initial primary chemotherapy/primary adjuvant therapy include intravenous with [or without] IP options (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–IV in the NCCN Guidelines for Epithelial Ovarian Cancer).\(^{194}\) All of the regimens (including the combined intravenous/IP chemotherapy) may be used for epithelial ovarian, primary peritoneal, and Fallopian tube cancers. The intravenous/IP chemotherapy regimen (IP chemotherapy) is recommended for patients with stage III cancer with optimally debulked (<1 cm residual) disease based on randomized controlled trials (category 1).\(^{174,195,196}\) Women with stage II disease may also receive IP chemotherapy, although no randomized evidence for stage II has been published.

In women with stage III cancer, survival was increased by 16 months after IP therapy using cisplatin/paclitaxel when compared with standard intravenous therapy (65.6 vs. 49.7 months, \(P = .03\)) in the GOG 172 trial. For patients who are not candidates for IP therapy (eg, those with poor performance status [PS]), other regimens may be recommended (see Primary Chemotherapy/Primary Adjuvant Therapy in the NCCN Guidelines for Epithelial Ovarian Cancer).\(^{184,197}\) Intravenous docetaxel plus carboplatin (category 1)\(^{198}\) or paclitaxel plus cisplatin (category 1) are options for alternative regimens.\(^{199}\) The docetaxel/carboplatin regimen may be considered for patients who are at high risk for neuropathy (eg, patients with diabetes). Recommendations for the number of cycles of treatment vary with the stage of the disease. For patients with advanced-stage disease (stages II–IV), 6 to 8 cycles of chemotherapy are recommended, whereas 3 to 6 cycles are recommended for earlier-stage disease.\(^{200}\) Some clinicians feel there is a potential survival advantage for 6 cycles of chemotherapy in patients with serous cytology.\(^{201}\)

The recommended intravenous regimens accepted by a consensus of the NCCN Panel include: 1) paclitaxel, 175 mg/m\(^2\) over 3-hour intravenous infusion, followed by carboplatin, dosed at an area under the curve (AUC) of 5 to 6 intravenous over 1 hour on day 1, given every 3 weeks for 6 cycles (category 1);\(^{197,202}\) 2) dose-dense paclitaxel, 80 mg/m\(^2\) intravenous over 1 hour on days 1, 8, and 15 plus carboplatin AUC 5 to 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1);\(^{203}\) 3) paclitaxel 60 mg/m\(^2\) over 1 hour followed by carboplatin AUC 2 IV over 30 minutes, weekly for 18 weeks (category 1);\(^{204}\) and 4) docetaxel, 60 to 75 mg/m\(^2\) 1-hour intravenous infusion followed by carboplatin, dosed at AUC of 5 to 6 intravenous over 1 hour on day 1, every 3 weeks for 6 cycles (category 1).\(^{198}\)
For the 2015 update, the NCCN Panel added the weekly carboplatin/paclitaxel regimen and suggests considering the weekly regimen for elderly patients or those with poor PS based on the phase III MITO-7 trial. Note that carboplatin dosing may be revised based on changes in serum creatinine methodology. These intravenous regimens may also be used for neoadjuvant chemotherapy (see Principles of Chemotherapy in the NCCN Guidelines for Ovarian Cancer). For the 2015 update, the NCCN Panel revised the AUCs for carboplatin to 5 to 6 to reflect contemporary treatment.

The recommended IP chemotherapy regimen is paclitaxel, 135 mg/m² continuous intravenous infusion over 3 or 24 hours on day 1; cisplatin, 75 to 100 mg/m² IP on day 2 after intravenous paclitaxel; paclitaxel, 60 mg/m² IP on day 8; repeat every 3 weeks for 6 cycles (category 1). The published randomized trial for this IP/intravenous regimen used intravenous continuous infusion of paclitaxel over 24 hours. A 3-hour infusion of paclitaxel has not been proven to be equivalent to a 24-hour infusion, although a 3-hour infusion has been reported to be more convenient, easier to tolerate, and less toxic. Note that these IP regimens include intravenous regimens so that systemic disease can also be treated. All of these regimens have different toxicity profiles. The docetaxel/carboplatin regimen is associated with increased risk for neutropenia; the intravenous paclitaxel/carboplatin regimen is associated with sensory peripheral neuropathy, and dose-dense paclitaxel is associated with increased anemia and decreased quality of life. Note that there are no agents to prevent chemotherapy-induced peripheral neuropathy.

The IP paclitaxel/cisplatin regimen is associated with leukopenia, infection, fatigue, renal toxicity, abdominal discomfort, and neurotoxicity. In the initial studies, only 42% of women were able to complete all 6 treatment cycles (of the IP regimen) because of toxicity; however, with more experience, this percentage has improved in the major cancer centers. Using a lower IP cisplatin dose of 75 mg/m² or splitting the dose may help to decrease toxicity. This approach is currently under investigation in an ongoing GOG clinical trial. Patients considered for the IP cisplatin and IP/intravenous paclitaxel regimen should have normal renal function before starting, a medically appropriate PS based on the future toxicities of the IP/intravenous regimen, and no previous evidence of medical problems that could significantly worsen during chemotherapy (eg, preexisting neuropathy) (see Principles of Chemotherapy in the NCCN Guidelines for Epithelial Ovarian Cancer). Reasons for discontinuing the IP regimen included catheter complications, nausea/vomiting/dehydration, and abdominal pain. Women unable to complete IP therapy should receive intravenous therapy. Techniques to decrease catheter complications include catheter choice and timing of insertion. Expert nursing care may help to decrease complications. Giving intravenous hydration before and after IP chemotherapy is a useful strategy to prevent renal toxicity. After chemotherapy, patients often require intravenous fluids (5–7 days) in the outpatient setting to prevent or help treat dehydration. Whether to use IP or intravenous chemotherapy remains controversial.

Patients with poor PS, comorbidities, stage IV disease, or advanced age (>65 years) may not tolerate the IP regimen or the other combination intravenous regimens described in the NCCN Guidelines. Single-agent platinum agents, such as cisplatin or carboplatin, may be more appropriate for these patients. A recent phase III randomized trial (MITO-7) assessed giving carboplatin/paclitaxel every week compared with standard therapy given every 3 weeks (ie, intravenous carboplatin/paclitaxel) in women with advanced epithelial ovarian cancer. Median PFS was similar between the 2 regimens. The weekly
carboplatin/paclitaxel regimen was associated with fewer side effects and yielded a better quality of life. For example, fewer patients receiving the weekly regimen had grade 3 to 4 neutropenia (167 [42%] of 399 patients vs. 200 [50%] of 400 patients). For the 2015 update, the NCCN Panel suggests considering this weekly carboplatin/paclitaxel regimen for elderly patients or those with poor PS based on the phase III MITO-7 trial. Algorithms are available for predicting chemotherapy toxicity (see the NCCN Guidelines for Senior Adult Oncology, available at NCCN.org).

The IP regimen published by Armstrong et al has, however, documented the longest median survival (65.6 months) that has been described to date in women with optimally debulked stage III cancer. A recent study reported overall survival of 110 months in patients with stage III ovarian cancer and no residual disease who received the IP regimen. Another recent study showed that survival improves with each cycle of IP chemotherapy. Patients with primary peritoneal cancer, Fallopian tube cancer, or MMMT can also be considered for IP chemotherapy. All women should be counseled about the clinical benefit associated with combined intravenous and IP chemotherapy administration before undergoing surgery for epithelial ovarian cancer, Fallopian tube cancer, primary peritoneal cancer, or MMMT. A recent study reported that women with aberrant BRCA1 expression had increased survival when treated with IP cisplatin/paclitaxel.

Dose-dense weekly paclitaxel with carboplatin has been shown to increase both PFS (28 vs. 17 months, \(P = .0037\)) and overall survival when compared with standard therapy given every 3 weeks (ie, intravenous carboplatin/paclitaxel) in women with advanced epithelial ovarian cancer. In the dose-dense group, median overall survival was 100.5 months versus 62.2 months in the conventional treatment group (HR 0.79, 95% CI 0.63–0.99; \(P = .039\)). However, the dose-dense regimen is more toxic, and patients discontinued dose-dense paclitaxel therapy more often than did those receiving standard therapy. Future studies will compare the effect of weekly paclitaxel on the overall survival benefit with that of using IP chemotherapy.

**Anti-Angiogenesis Agents**

A phase III randomized trial (GOG 0218) assessed bevacizumab combined with carboplatin/paclitaxel in the upfront setting compared to carboplatin/paclitaxel alone. The median PFS was significantly increased (14.1 vs. 10.3 months, \(P < .001\)) in patients receiving prolonged bevacizumab (upfront and as maintenance therapy) when compared with chemotherapy alone. However, PFS was not significantly increased in patients who did not receive maintenance bevacizumab (upfront with placebo maintenance) versus chemotherapy alone (ie, bevacizumab/carboplatin/paclitaxel vs. carboplatin/paclitaxel). Quality of life was not improved in GOG 0218. Another phase III randomized trial (ICON7) also assessed bevacizumab/carboplatin/paclitaxel in the upfront setting. The trial design of ICON7 differs from GOG 0218 (see next paragraph).

Although the PFS data from ICON7 confirm the findings of GOG 0218, the benefits appear to be modest (2.4-month increase in PFS) and mature survival data have not been reported. Panel members had a major disagreement about recommending the addition of bevacizumab to upfront chemotherapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy, which is reflected in the category 3 recommendations for these regimens (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–IV in the NCCN Guidelines for Epithelial Ovarian Cancer). Many panel members believe that bevacizumab should not
be added to upfront chemotherapy in patients with ovarian cancer, because data from these 2 phase III randomized trials (ie, GOG 0218, ICON7) have not shown a statistically significant increase in overall survival and/or improved quality of life. Note that a category 3 recommendation is based on any level of evidence (eg, even phase III randomized trials), but fewer (<50%) panel members agree that the intervention is appropriate.

The NCCN Panel recommends (category 3) that if bevacizumab is used with upfront chemotherapy followed by maintenance therapy, then either the GOG 0218 or ICON7 regimens should be used (see Primary Chemotherapy/Primary Adjuvant Chemotherapy Regimens for Stage II–IV in the NCCN Guidelines for Epithelial Ovarian Cancer). The only GOG 0218 regimen that is recommended (category 3) is the prolonged bevacizumab regimen (upfront with carboplatin/paclitaxel followed by maintenance bevacizumab). This topic is discussed in greater detail in the recently published NCCN Guidelines Insights: Ovarian Cancer. The NCCN Panel encourages participation in ongoing clinical trials that are further investigating the role of anti-angiogenesis agents in the treatment of ovarian cancer, both in the upfront and recurrence settings.

**Number of Chemotherapy Cycles and Agents**

Panel members had an extensive discussion about the number of cycles of chemotherapy that should be recommended for patients with advanced-stage disease. There is no evidence confirming that more than 6 to 8 cycles of combination chemotherapy are required for initial chemotherapy. Patients with stage II to IV disease may receive 3 to 6 cycles of chemotherapy followed by completion surgery and postoperative chemotherapy (see Primary Treatment in the NCCN Guidelines for Epithelial Ovarian Cancer).

The role of maintenance (or postremission) therapy in patients who achieve a complete clinical remission after 6 to 8 cycles of chemotherapy is an option based on the results from GOG 178. This trial randomly assigned patients to 3 versus 12 months of further paclitaxel (135–175 mg/m² every 4 weeks for 12 cycles) after initial chemotherapy. The published study treated patients at 175 mg/m²; the plan was to decrease the dose to 135 mg/m², but the protocol closed before any patients were treated at the lower dose. The results of this trial suggest that patients receiving 12 months of therapy sustained a PFS advantage. However, postremission paclitaxel chemotherapy is a category 3 recommendation because it is associated with toxicity and it only increased PFS.

For the 2015 update, the NCCN Panel recommended adding pazopanib (category 2B) as maintenance therapy for patients with stages II to IV epithelial ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer who have had complete clinical remission after first-line therapy. This recommendation is based on a recent phase III randomized trial showing an increase in PFS (17.9 vs. 12.3 months) in patients treated with pazopanib compared with placebo. However, pazopanib is a category 2B recommendation for maintenance therapy because the FDA has not approved this indication, there was no increase in overall survival data, and patients had increased toxicity with pazopanib such as grade 3 or 4 hypertension. Bevacizumab may be continued after primary systemic therapy if an upfront chemotherapy/bevacizumab regimen was used, but there are no data to support introducing bevacizumab as maintenance therapy if other initial primary regimens were used.
Drug Reactions
Virtually all drugs have the potential to cause adverse reactions (infusion reactions or allergies), either during or after the infusion.\textsuperscript{236-238} Drugs used in gynecologic oncology treatment that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, and paclitaxel. Drug reactions can occur with either intravenous or IP administration of these drugs.\textsuperscript{239} Most of these drug reactions are mild infusion reactions (ie, skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (ie, life-threatening anaphylaxis) can occur.\textsuperscript{240,241} Infusion reactions are more common with paclitaxel,\textsuperscript{242} but mild reactions can also occur with liposomal doxorubicin.\textsuperscript{243} Allergic reactions (ie, true drug allergies) are more common with platinum agents (ie, carboplatin, cisplatin, oxaliplatin).\textsuperscript{242,244}

Management of drug reactions is discussed in the NCCN Guidelines for Ovarian Cancer. Algorithms are provided for management of mild, severe, and life-threatening reactions.\textsuperscript{245} These drug reaction algorithms are also useful for patients with other gynecologic cancers (eg, cervical and uterine cancers) who are receiving carboplatin, cisplatin, docetaxel, liposomal doxorubicin, oxaliplatin, or paclitaxel. Typically, the infusion should be stopped for patients having a reaction; further management is provided in the algorithms. Standard resuscitation procedures (ie, Advanced Cardiovascular Life Support [ACLS]) should be followed for patients with acute cardiopulmonary arrest.\textsuperscript{246-248}

For patients with allergic reactions, various desensitization protocols are recommended. To maximize safety, patients may be desensitized in the intensive care unit.\textsuperscript{238,249} Almost all patients can be desensitized (about 90%).\textsuperscript{238} For severe life-threatening reactions, the implicated agent should not be used again unless under the supervision and guidance of an allergist or specialist with expertise in desensitization. If a mild allergic reaction is suspected, and it is appropriate to administer the drug again, a desensitization regimen should be used even if the symptoms have resolved.\textsuperscript{236} Patients must be desensitized with each infusion if they previously had a drug reaction.\textsuperscript{250-252} Data suggest that an extended infusion schedule and use of premedication may decrease the number of hypersensitivity reactions to carboplatin.\textsuperscript{253} Skin testing is associated with false-negative results.\textsuperscript{254,255}

Radiation Therapy
Whole abdominal radiation therapy is rarely used for epithelial ovarian, primary peritoneal, and Fallopian tube cancers in NCCN Member Institutions. It is not included as a treatment recommendation in the NCCN Guidelines for Ovarian Cancer. Palliative localized RT is an option for symptom control in patients with recurrent disease (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{256-260} Patients who receive radiation are prone to vaginal stenosis, which can impair sexual function. Women can use vaginal dilators to prevent or treat vaginal stenosis. Dilator use can start 2 to 4 weeks after RT is completed and can be done indefinitely.\textsuperscript{261}

Recommendations After Primary Treatment
After initial treatment (eg, 6 cycles of chemotherapy), patients should undergo a clinical re-evaluation. Observation with follow-up is recommended for patients who have no evidence of progression of cancer (ie, complete clinical remission) after initial treatment (see Follow-Up Recommendations in this Discussion) (also see Monitoring/Follow-up in the NCCN Guidelines for Epithelial Ovarian Cancer); other options are discussed below. Patients with partial remission or progression during initial treatment should be treated with second-line approaches (see Recurrent Disease in this Discussion) (see Therapy for Persistent Disease or Recurrence in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{262,263} The NCCN Guidelines...
recommend symptom management and best supportive care for all patients; patients should be referred for palliative care assessment if appropriate (see the NCCN Guidelines for Palliative Care, available at NCCN.org). The NCCN Guidelines also recommend that all patients with ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer be referred for genetic risk evaluation (see the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, available at NCCN.org).^{103,104}

Options for maintenance treatment—for the management of patients with advanced-stage (stages II–IV) disease who are in complete clinical remission after their initial therapeutic regimen—include observation alone, a clinical trial, or additional systemic therapy^{232} (eg, pazopanib [category 2B], paclitaxel [category 3]), preferably in a controlled clinical trial (see Secondary Adjuvant Therapy in the NCCN Guidelines for Epithelial Ovarian Cancer). For the 2015 update, the NCCN Panel added a recommendation for maintenance pazopanib (category 2B) for management of stage II to IV disease (see Number of Chemotherapy Cycles and Agents in this Discussion).^{235} As previously described, maintenance pazopanib increases PFS when administered following initial chemotherapy. Note that a category 2B recommendation is based on lower level evidence (eg, phase II randomized trials) and a majority vote (>50% but <85%) from panel members who agree that the intervention is appropriate. If used, the recommended paclitaxel regimen is 135 to 175 mg/m\(^2\) every 4 weeks for 12 cycles.^{232} Use of maintenance bevacizumab (category 3) is discussed in an earlier section and has been shown to modestly increase PFS when administered following initial chemotherapy that included bevacizumab (see Anti-Angiogenesis Agents in this Discussion). Note that complete clinical remission is defined as no objective evidence of disease (ie, negative physical examination, negative CA-125 levels, negative CT with <1 cm lymph nodes).^{262,263}

**Follow-up Recommendations**

Recurrent disease may be identified clinically (eg, pelvic pain, weight loss), biochemically (ie, elevated CA-125 levels), and/or with imaging following initial treatment. After the completion of primary surgery and chemotherapy in patients with all stages of ovarian cancer (or Fallopian tube cancer or primary peritoneal cancer) who have a complete response, the standard recommendation is observation with follow-up to monitor for recurrent disease. Recommendations for monitoring are described in the algorithm (see Monitoring/Follow-up in the NCCN Guidelines for Epithelial Ovarian Cancer). Chest/abdominal/pelvic CT, MRI, PET scans (category 2B for PET), PET/CT, and chest imaging may be ordered if clinically indicated.^{264-267} Patients should be educated about the signs and symptoms suggestive of recurrence (eg, pelvic pain, bloating, early satiety, obstruction, weight loss, fatigue). Patients who have had fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery should be considered (category 2B) after they finish childbearing.

If the CA-125 level was initially elevated, the measurement of a CA-125 level or other tumor markers is recommended. A multi-institutional European trial assessed the use of CA-125 for monitoring for ovarian cancer recurrence after primary therapy.^{268,269} The data suggest that treating recurrences early (based on detectable CA-125 levels in patients who are asymptomatic) is not associated with an increase in survival and is associated with a decrease in quality of life.^{270} Recommendations from the SGO state that use of CA-125 levels for surveillance is optional.^{266} The NCCN Panel feels that the European trial has limitations and patients should discuss the pros and cons of CA-125
monitoring with their physicians. In addition, patients seem reluctant to
give up monitoring.271 Others have discussed this study in greater
detail.272-274

Management of an Increasing CA-125 Level
The management of patients in a clinical complete remission is
somewhat controversial; this includes patients who are found to have an
increasing CA-125 level (during routine monitoring and follow-up) but no
signs or symptoms of recurrent disease (eg, pelvic pain, bloating,
obstruction), following an evaluation including a negative pelvic
examination and negative chest/abdominal/pelvic CT scans. Patients
who have never received chemotherapy (ie, naïve to chemotherapy)
should be managed using recommendations for newly diagnosed
patients, should undergo clinically appropriate imaging studies and
surgical debulking, and should be treated as previously described (see
Primary Treatment in the NCCN Guidelines for Epithelial Ovarian
Cancer).

Recurrence therapy refers to drugs, radiation, or other treatment that is
given to decrease tumor burden, control symptoms, or increase length
and/or quality of life for patients with recurrent disease. After the
documentation of an increased CA-125 level (ie, biochemical relapse),
the median time for a clinical relapse is 2 to 6 months. However, data
suggest that immediate treatment for biochemical relapse is not
beneficial; therefore, immediate treatment is a category 2B
recommendation in the NCCN Guidelines.268 After biochemical relapse,
recommended options include enrollment in a clinical trial or delaying
treatment (ie, observation) until clinical symptoms arise (see Recurrent
Disease in the NCCN Guidelines for Epithelial Ovarian Cancer).
Because tamoxifen and other hormonally active agents have a defined
response rate for patients with recurrent disease who have progressed
after platinum-based chemotherapy,275 these agents are frequently
administered to patients who have only a rising CA-125 level276 as
evidence of tumor progression.277 Tamoxifen, other hormonal agents, or
other recurrence therapy are acceptable recommendations for this
clinical situation (category 2B for all).

Recurrent Disease
The prognosis is poor either 1) for patients who progress after 2
consecutive chemotherapy regimens without ever sustaining a clinical
benefit (refractory),278 or 2) for those whose disease recurs in less than
6 months (platinum resistant). Note that progression is typically defined
using RECIST (Response Evaluation Criteria in Solid Tumor)
criteria.262,263 Panel members emphasized the importance of clinical
trials to identify agents active in this group of patients. Because these
patients were resistant to their primary induction regimen, retreatment
with a platinum compound or paclitaxel is not generally recommended.
Although panel members do not recommend retreatment with platinum
agents, they recognize that altering the schedule of paclitaxel may
produce secondary responses.279,280 Before any drug is given in the
recurrent setting, the clinician should be familiar with the drug’s
metabolism and should make certain that the patient is an appropriate
candidate for the drug (eg, that the patient has adequate renal or
hepatic function). Clinical judgment must be used when selecting
postoperative chemotherapy.

Options for patients with platinum-resistant disease or for those with
stages II to IV disease who have a partial response include clinical trial,
recurrence therapy (see Acceptable Recurrence Therapies in the NCCN
Guidelines for Epithelial Ovarian Cancer),281 and/or best supportive care
(see NCCN Guidelines for Palliative Care, available at NCCN.org).
Although palliative care is appropriate at many stages during the
disease course, an assessment for palliative care is especially
appropriate for women with platinum-resistant disease who may be receiving continuous systemic therapy. Patients who relapse 6 months or more after initial chemotherapy are termed platinum sensitive.\textsuperscript{282,283} Combination platinum-based chemotherapy is preferred for first recurrence (category 1) in patients with platinum-sensitive disease (see \textit{Therapy for Persistent Disease or Recurrence} in the NCCN Guidelines for Epithelial Ovarian Cancer); other recurrence therapies are also an option.\textsuperscript{283,284} Possible regimens are discussed in the following section (see \textit{Acceptable Recurrence Modalities} in this Discussion).

Patients with ovarian cancer will often be retreated with multiple courses of recurrence therapy. Caution should be used in patients who receive multiple sequential courses of chemotherapy, because they may experience excessive toxicity and may not be able to tolerate doses used for first-line recurrence therapy; thus, clinical judgment should be used when selecting doses (see \textit{Principles of Chemotherapy} in the NCCN Guidelines for Epithelial Ovarian Cancer). Potential, ancillary, palliative, surgical, and/or supportive care procedures for selected patients are summarized in the algorithm (see \textit{Principles of Surgery} in the NCCN Guidelines for Epithelial Ovarian Cancer).

Secondary cytoreductive surgery can be considered for patients who recur (ie, radiographic and/or clinical relapse) after a long disease-free interval (6 months or more).\textsuperscript{159,291-295} A meta-analysis suggests that survival increases for patients with recurrent disease who have complete cytoreduction.\textsuperscript{160} The duration of the disease-free interval has not been established, although panel members agreed that it should be at least 6 months before surgery is considered.\textsuperscript{138,296}

\textbf{Acceptable Recurrence Modalities}\n
The NCCN Panel felt that no single therapeutic agent should be currently recommended as the treatment of choice for recurrent ovarian carcinoma. However, some agents are preferred based on expert opinion primarily for reasons of decreased toxicity and/or marginally increased effectiveness (see \textit{Acceptable Recurrence Therapies} in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{194} A meta-analysis of chemotherapy for recurrent ovarian cancer was published in 2007.\textsuperscript{282} Recurrence therapy refers to therapy (eg, drugs, radiation, or other treatment) that is given for recurrent cancer to control symptoms and increase length or quality of life for clinical, biochemical, or radiographic evidence of recurrent cancer following initial treatment.

The consensus of the NCCN Panel for the treatment of recurrent disease is shown in the algorithm (see \textit{Acceptable Recurrence Therapies} in the NCCN Guidelines for Epithelial Ovarian Cancer). Platinum-based combination chemotherapy is recommended (category 1) for platinum-sensitive recurrence (see \textit{Therapy for Persistent Disease or Recurrence} in the NCCN Guidelines for Epithelial Ovarian Cancer).\textsuperscript{282,283} Preferred combinations for platinum-sensitive recurrent disease include carboplatin/paclitaxel (category 1),\textsuperscript{283} carboplatin/liposomal doxorubicin (category 1),\textsuperscript{297-299} carboplatin/weekly paclitaxel,\textsuperscript{203} carboplatin/docetaxel,\textsuperscript{300,301} carboplatin/gemcitabine (which has been shown to improve PFS),\textsuperscript{283,302,303} or cisplatin/gemcitabine.\textsuperscript{302} For the 2015 update, the NCCN Panel revised the recommendation for carboplatin/liposomal doxorubicin to category 1 (from category 2A) based on recent data and uniform consensus from the panel.\textsuperscript{297,298,304-307} Carboplatin/liposomal doxorubicin is equivalent to carboplatin/paclitaxel but both have different toxicity profiles. Carboplatin/liposomal doxorubicin is easier to tolerate; women tend to discontinue therapy with carboplatin/paclitaxel more often than they do with carboplatin/liposomal doxorubicin.

For platinum-resistant disease, the preferred single agent is a non-platinum–based agent (ie, docetaxel, oral etoposide, gemcitabine,
liposomal doxorubicin, weekly paclitaxel, topotecan); sequential therapy using single agents is typically used. The response rate of the following agents appears to be similar: topotecan, 20%; gemcitabine, 19%; liposomal doxorubicin, 26%; and oral etoposide, 27%. In patients with platinum-resistant disease, the response rate for docetaxel is 22% and for weekly paclitaxel is 21%. For platinum-sensitive disease in patients who cannot tolerate combination therapy, the preferred single agent is carboplatin or cisplatin. Recent reports suggest that weekly topotecan is less toxic than the daily regimen.

Other potentially active agents include altretamine, capecitabine, cyclophosphamide, doxorubicin, ifosfamide, irinotecan, melphalan, oxaliplatin, paclitaxel, nanoparticle albumin-bound paclitaxel (ie, nab-paclitaxel), pemetrexed, and vinorelbine (see Acceptable Recurrence Therapies in the NCCN Guidelines for Epithelial Ovarian Cancer). Nab-paclitaxel has an overall response rate of 64%. Vinorelbine has a response rate of 20%. Altretamine has a 14% response rate and ifosfamide has a 12% response rate, although less information is available regarding their use in patients with paclitaxel-refractory disease. In women with platinum-resistant disease, the response rate for pemetrexed is 21%. Bevacizumab is also active (21%) in patients with both platinum-sensitive and platinum-resistant disease, although it may cause hypertension, arterial thrombosis, or intestinal perforation.

Several phase III randomized trials have recently assessed combination therapy with bevacizumab for recurrent ovarian cancer (ie, AURELIA, OCEANS). The AURELIA trial assessed bevacizumab combined with chemotherapy---either liposomal doxorubicin, weekly paclitaxel, or topotecan---versus chemotherapy alone in patients with advanced platinum-resistant ovarian cancer. For patients receiving bevacizumab/chemotherapy, the primary endpoint of PFS was 6.7 months versus 3.4 months with chemotherapy alone. The median overall survival was 16.6 months for the bevacizumab/chemotherapy arm versus 13.3 months for chemotherapy alone; the overall survival hazard ratio was 0.85 (95% CI, 0.66–1.08; P < .174). Hypertension and proteinuria (≥ grade 2) were more common with bevacizumab. Gastrointestinal perforation occurred in 2.2% of patients on the bevacizumab arm. Based on the results of the AURELIA trial, the NCCN panel now recommends the following combination regimens for patients with platinum-resistant recurrent ovarian cancer: weekly paclitaxel/bevacizumab, liposomal doxorubicin/bevacizumab, and topotecan/bevacizumab. These bevacizumab combination regimens are contraindicated in patients at increased risk of gastrointestinal perforation or those who have previously received bevacizumab. Previously, only single-agent therapy was recommended for platinum-resistant disease.

A phase III randomized trial (OCEANS) assessed carboplatin/gemcitabine with and without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer who had not previously received bevacizumab. In the OCEANS trial, PFS was increased in patients receiving the chemotherapy/bevacizumab arm when compared with chemotherapy alone (12.4 vs. 8.4 months, P < .0001). Combination therapy with bevacizumab is a category 2B recommendation for platinum-sensitive disease, because there is less consensus among the NCCN Panel (>50% but < 85%) that this intervention is appropriate. Panel members feel other combination regimens may be more preferred for platinum-sensitive disease than regimens with bevacizumab. In addition, the carboplatin/gemcitabine/bevacizumab regimen is only recommended in patients who have not previously received bevacizumab. Based on
phase II trials, panel members feel that bevacizumab alone is useful in patients who have recurrent disease (especially those with ascites), which is reflected in the category 2A recommendation for single-agent bevacizumab for women with either platinum-sensitive or platinum-resistant disease.\(^{119,308,330,336}\)

Single-agent paclitaxel, nab-paclitaxel, and oxaliplatin are listed as other potentially active agents that can be used in appropriate patients.\(^{232,283,314,337}\) Capecitabine has activity in patients resistant to platinum and taxanes.\(^{338}\) Other alkylating agents, including cyclophosphamide and melphalan, can also be used.\(^{199,339}\) In addition, hormonal therapy with tamoxifen or other agents including aromatase inhibitors (such as exemestane, anastrozole, and letrozole), leuprolide acetate, or megestrol acetate continues to be a viable therapeutic option for patients who cannot tolerate or have not responded to cytotoxic regimens.\(^{340-346}\)

Recent data suggest that olaparib (AZD2281), which is a PARP (poly ADP-ribose polymerase) inhibitor, is active in select patients (those with \(BRCA1\) and \(BRCA2\) mutations have higher response rates than those who are \(BRCA\) negative) with chemotherapy-refractory ovarian cancer, especially those with platinum-sensitive disease.\(^{308,347,351}\) Patients who are resistant or refractory to platinum have a lower response rate to olaparib.\(^{348,350}\) A recent trial assessed olaparib in women with recurrent advanced ovarian cancer; the overall response rate was 34% (CR, 2%; and PR, 32%).\(^{352,355}\) The FDA recently approved olaparib for patients with advanced ovarian cancer who have received treatment with 3 or more lines of chemotherapy and who have a germline \(BRCA\) mutation.\(^{353,354}\) For the 2015 update, the NCCN Panel now recommends olaparib as recurrence therapy for patients with advanced ovarian cancer who have received 3 or more lines of chemotherapy and who have a germline \(BRCA\) mutation (detected using an approved FDA test or other validated test performed in a CLIA-approved facility) based on this trial and the recent FDA approval. However, the NCCN Panel decided not to recommend olaparib as maintenance therapy for patients with platinum-sensitive disease, because panel members feel that current data are not sufficient for recommending olaparib in this setting.\(^{351,355}\) Studies are ongoing for olaparib in other rare populations such as patients with HR deficiency.\(^{356,357}\)

Chemotherapy/resistance assays and/or other biomarker assays are being used in some NCCN Member Institutions to aid in selecting chemotherapy in situations where there are multiple equivalent chemotherapy options available; however, the current level of evidence (category 3) is not sufficient to supplant standard-of-care chemotherapy.\(^{358,359}\) Thus, the NCCN Panel felt that in vitro chemosensitivity testing to choose a chemotherapy regimen for recurrent disease situations should not be recommended (category 3), owing to the lack of demonstrable efficacy for such an approach. ASCO also does not recommend use of chemotherapy sensitivity and resistance assays, unless in a clinical trial setting.\(^{360}\)

However, regardless of which regimen is selected initially, reevaluation should follow after 2 to 4 cycles of chemotherapy (depending on the agent) to determine if patients benefited from chemotherapy. Patients who primarily progress on 2 consecutive chemotherapy regimens without evidence of clinical benefit may not benefit from additional therapy.\(^{278}\) Decisions to offer supportive care, additional therapy, or clinical trials should be made on a highly individual basis. Localized RT can also provide effective palliation when radiation ports are tailored to specific symptomatic disease sites.\(^{256,257}\)
Less Common Ovarian Histopathologies

Less common histopathologies of ovarian cancer include: malignant germ cell neoplasms, carcinosarcomas (MMMTs), malignant sex cord-stromal tumors, and ovarian LMP tumors. These tumors account for approximately 5% of all ovarian cancers and differ from epithelial ovarian cancer in their biology and recommended approaches to treatment. In contrast to epithelial ovarian cancer, many patients with these tumors present at an early stage and tumors may be confined to one ovary; thus, some of these patients are candidates for fertility-sparing surgery, which may be done laparoscopically (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer).

The diagnosis of LCOH is often not made until after surgery.

Recommended Workup

Patients may obtain consultation at an NCCN Member Institution for recommendations and treatment of an undiagnosed pelvic mass, or for management of a previously biopsied malignant ovarian tumor. Many such patients come to NCCN Member Institutions after having had previous surgery at other institutions. Patients having a histologically undiagnosed pelvic mass should undergo evaluation and staging as described in the algorithm (see Workup in the NCCN Guidelines for Less Common Ovarian Histopathologies). The workup for LCOH is similar to the workup for ovarian cancer. Tumor markers (including CA-125, inhibin, AFP, and beta-HCG) can be measured if clinically indicated. Women younger than 35 years with a pelvic mass should have AFP levels measured to assess for germ cell tumors.

Women desiring to potentially maintain fertility should have an intraoperative frozen section evaluation. Fertility-sparing surgery may be performed (if technically feasible) if the frozen section results are positive for malignant germ cell tumor, ovarian cancer of LMP, or clinical stage I epithelial ovarian or stromal tumors. Patients who do not desire fertility preservation; those who have a clinical stage II, III, or IV epithelial ovarian cancer or stromal tumor; or those with carcinosarcoma (MMMT) should undergo comprehensive surgical staging as per the ovarian cancer guidelines (see Principles of Surgery in the NCCN Guidelines for Ovarian Cancer).

Patients may have been referred to an NCCN Member Institution after receiving a diagnosis of an LCOH tumor. The recommended initial surgical recommendation depends on the specific histologic diagnosis. Often, patients have been comprehensively staged (having met the standards for surgical staging of the GOG) and have undergone cytoreductive surgery. However, in some instances, they are referred after having had incomplete staging (ie, uterus and/or adnexa intact, omentum not removed, surgical stage not documented).

Malignant Germ Cell Tumors

These tumors include dysgerminomas, immature teratomas, embryonal tumors, and endodermal sinus (yolk sac) tumors; they mainly occur in younger women who are often diagnosed with stage I disease. The recommended workup (see Recommended Workup as previously discussed) for malignant germ cell tumors may include pulmonary function studies if bleomycin is being considered. In young women (<35 years) with a pelvic mass, AFP levels can indicate the presence of germ cell tumors. Malignant germ cell tumors have an excellent prognosis. After appropriate treatment, 5-year survival is more than 85%.

Treatment

Completion surgery with comprehensive staging is recommended as initial surgery for patients who do not desire fertility preservation. The staging system for ovarian and primary peritoneal cancer is also used.
for malignant germ cell tumors (see Table 1 in the NCCN Guidelines for Ovarian Cancer). After comprehensive surgical staging, observation is recommended for patients with stage I dysgerminoma or immature teratoma.\textsuperscript{371} Surgery for children or adolescents may differ from that for adult women (see \textit{Principles of Surgery} in the NCCN Guidelines for Ovarian Cancer). In children or adolescents with early-stage germ cell tumors, comprehensive staging may be omitted.\textsuperscript{372,373} If these patients have had incomplete surgical staging, recommended options depend on the type of tumor, the results of imaging and tumor marker testing (eg, AFP, beta-HCG), the age of the patient, and whether the patient desires fertility preservation (see \textit{Malignant Germ Cell Tumors} in the NCCN Guidelines for Less Common Ovarian Histopathologies). Fertility-sparing surgery should be considered for those desiring fertility preservation, regardless of stage (see \textit{Primary Treatment for Malignant Germ Cell Tumors} in the NCCN Guidelines for Less Common Ovarian Histopathologies).\textsuperscript{114,367,370,374-376} Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery (category 2B) should be considered after finishing childbearing.

After surgery, surveillance is the recommended option for patients with stage I dysgerminoma or stage I, grade I immature teratoma based on European and pediatric reports.\textsuperscript{377-380} Observation or chemotherapy may be considered for children or adolescents with select stage IA tumors (see the NCCN Guidelines for Malignant Germ Cell Tumors).\textsuperscript{367,377,379,381-383} For patients with stage II to IV malignant germ cell tumors, postoperative chemotherapy is recommended (see \textit{Acceptable Primary and Recurrence Therapies for Malignant Germ Cell Tumors} in the NCCN Guidelines for Less Common Ovarian Histopathologies). Postoperative chemotherapy for 3 to 4 cycles with bleomycin/etoposide/cisplatin (BEP) (category 2B for 3 vs. 4 cycles) is recommended for: 1) embryonal tumors or endodermal sinus tumors; 2) stages II to V dysgerminoma; or 3) stage I, grade 2 to 3, or stage II to IV immature teratoma (see the NCCN Guidelines for Testicular Cancer, available at NCCN.org).\textsuperscript{368,384-386} If considering the use of bleomycin, pulmonary function tests are recommended.\textsuperscript{368,369} Although most clinicians avoid a 3-week BEP regimen, some feel that a 3-week BEP regimen (3 cycles) may be useful in patients with low-risk or stage 1 disease, although this is a category 2B recommendation; the Memorial Sloan Kettering Cancer Center criteria can be used to identify tumors that are low risk.\textsuperscript{377,387-394} However, the 4-cycle BEP regimen is recommended as the standard regimen until further data become available. In select patients with stage IB to III dysgerminoma for whom minimizing toxicity is critical, 3 courses of etoposide/carboplatin can be used (carboplatin 400 mg/m\textsuperscript{2} [AUC \textasciitilde 5–6] on day 1 plus etoposide 120 mg/m\textsuperscript{2} on days 1–3 every 4 weeks for 3 courses).\textsuperscript{395} Dose reductions or delays are not recommended even in the setting of neutropenia.

Patients achieving a complete clinical response after chemotherapy should be observed clinically every 2 to 4 months with AFP and beta-HCG levels (if initially elevated) for 2 years. For those with abnormal markers and definitive recurrent disease, options (category 2B) include: 1) high-dose chemotherapy;\textsuperscript{396} or 2) consider additional chemotherapy (see \textit{Acceptable Recurrence Therapies} in the NCCN Guidelines for Less Common Ovarian Histopathologies). Referral of these patients to a tertiary care center for potentially curative therapy is strongly recommended. Surveillance recommendations for germ cell tumors are described in the algorithm (see \textit{Surveillance for Germ Cell and Sex Cord-Stromal Tumors} in the NCCN Guidelines for Less Common Ovarian Histopathologies).\textsuperscript{266} Several case reports suggest that patients who have received chemotherapy for germ cell tumors may later present with growing teratoma syndrome.\textsuperscript{397-400}
Residual or Recurrent Disease
For patients having radiographic evidence of residual tumor (after surgery and chemotherapy) but with normal AFP and beta-HCG, consider surgical resection of the tumor; observation is also an option. Clinical judgment should be used regarding the frequency of imaging. Further options depend on which findings are present: residual malignancy, benign teratoma, or necrotic tissue (see Recurrent/Persistent Disease for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies). For patients with definitive residual disease and with persistently elevated AFP and/or beta-HCG after first-line chemotherapy, recommendations include TIP (paclitaxel, ifosfamide, cisplatin) or high-dose chemotherapy. Referral to a tertiary care center for potentially curative treatment is strongly recommended. There are small series but no major trials in adult patients.

Patients with recurrent or residual malignancy after multiple chemotherapeutic regimens for whom no curative options are considered possible may be treated with a recurrence modality (see Acceptable Primary and Recurrence Therapies for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies), including TIP, VAC ( vincristine, dactinomycin, cyclophosphamide), VeIP (vinblastine, ifosfamide, cisplatin), VIP (etoposide, ifosfamide, cisplatin), cisplatin/etoposide, docetaxel/carboplatin, paclitaxel/carboplatin, paclitaxel/gemcitabine, paclitaxel/ifosfamide, docetaxel, paclitaxel, high-dose chemotherapy, RT, or supportive care only. Combination chemotherapy is not recommended for patients with recurrent or residual disease who have no curative options. These recurrence regimens (see Acceptable Primary and Recurrence Therapies for Malignant Germ Cell Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies) are not generalizable for all of the uncommon histology tumors; therefore, patients should be referred to tertiary care institutions for treatment.

Malignant Sex Cord-Stromal Tumors
Malignant stromal tumors are rare and include granulosa cell tumors (most common), granulosa-theca tumors, and Sertoli-Leydig cell tumors; they are typically associated with a good prognosis. Most patients with granulosa tumors present with early-stage disease. It is important to determine whether the sex cord-stromal tumor is benign or malignant (see Sex Cord Stromal Tumors—WHO Histologic Classification in the NCCN Guidelines for Less Common Ovarian Histopathologies). The staging system for ovarian and primary peritoneal cancer is also used for sex cord-stromal tumors (see Table 1 in the NCCN Guidelines for Ovarian Cancer).

Patients with stage IA or IC sex cord-stromal tumors desiring to preserve their fertility should be treated with fertility-sparing surgery with complete staging. Although complete staging is recommended for all other patients, lymphadenectomy may be omitted. Patients who choose fertility-sparing surgery should be monitored by ultrasound examinations if necessary; completion surgery (category 2B) should be considered after finishing childbearing. For patients with high-risk stage I tumors (tumor rupture, stage 1C, poorly differentiated tumor, tumor size >10–15 cm), recommendations (all are category 2B) include observation or consideration of platinum-based chemotherapy. Those with surgical findings of low-risk stage I tumor (ie, without high-risk features) should be observed. For patients with granulosa cell tumors who are being observed, inhibin levels can be followed if they were initially elevated (category 2B). For patients with stage II to IV tumors, recommended options (all are category 2B) include RT for limited disease or platinum-based
chemotherapy (BEP or paclitaxel/carboplatin regimens are preferred). 417-420

Surveillance recommendations for sex cord-stromal tumors are provided in the algorithm, which are based on the SGO recommendations (see Surveillance for Germ Cell and Sex Cord-Stromal Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).266 Prolonged surveillance is recommended for granulosa cell tumors, because they can recur years later (eg, 30 years).375,408,409,421 For patients with stage II to IV tumors who subsequently have a clinical relapse, options include a clinical trial or recurrence therapy (see Acceptable Recurrence Therapies for Malignant Sex Cord-Stromal Tumors in the NCCN Guidelines for Less Common Ovarian Histopathologies).409,421-424 Note that bevacizumab or leuprolide may be considered for patients with recurrent granulosa cell tumors.424,425 Secondary cytoreductive surgery may also be considered.

Carcinosarcomas (Malignant Mixed Müllerian Tumors)

MMMTs are rare tumors with a poor prognosis.426-428 Most pathologists now consider MMMTs to be a variant of poor risk, poorly differentiated epithelial ovarian cancer (metaplastic carcinoma).429 Patients with MMMTs are not candidates for fertility-sparing surgery regardless of age. The staging system for ovarian and primary peritoneal cancer is also used for MMMTs (see Table 1 in the NCCN Guidelines for Ovarian Cancer).427

Optimal surgical debulking is recommended for patients with MMMTs (see Principles of Surgery in the NCCN Guidelines for Epithelial Ovarian Cancer).427,430-432 After complete surgical staging, patients with stage I to IV MMMT at the time of surgery should have postoperative chemotherapy. Patients with stage I to IV MMMT or recurrence are treated using the same chemotherapy regimens that are recommended for epithelial ovarian cancer (see Primary Chemotherapy/Primary Adjuvant Therapy in the NCCN Guidelines for Epithelial Ovarian Cancer).429,433-437 For example, the IP chemotherapy regimen described for ovarian cancer can be used for select patients with MMMT.

Ovarian Low Malignant Potential Tumors (Borderline Epithelial Ovarian Tumors)

Diagnosis

Ovarian LMP tumor (also known as borderline epithelial ovarian tumor, borderline ovarian tumor, or atypical proliferative tumor) is typically serous; other histologic subtypes can also occur.361 LMP is a primary epithelial ovarian lesion with cytologic characteristics suggesting malignancy but without frank invasion and with a clinically indolent course and good prognosis.438,439 Five-year survival exceeds 80%.440 In contrast to patients with frankly invasive ovarian carcinoma, women with ovarian LMP tumors tend to be younger, are often diagnosed with stage I disease, and are candidates for fertility-sparing surgery.441,442

Ovarian LMP tumors were recently moved to the algorithm for Less Common Ovarian Histopathologies because they are rare tumors and are managed differently than high-grade carcinomas.361,443 The characteristic pathologic hallmark of typical epithelial ovarian cancer is the identification of peritoneal implants, which microscopically and/or macroscopically invade the peritoneum. Ovarian LMP tumor has the visual appearance of peritoneal carcinomatosis. However, microscopic evaluation fails to reveal evidence of frank invasion by the tumor nodules, although rarely invasive implants (which continue to be consistent with the diagnosis of LMP lesions) can be identified microscopically by the pathologist.


**Treatment**

Treatment guidelines for ovarian LMP tumors depend on the histologic and clinical characteristics, the age of the patient, 

\[442\]

the stage of the disease at the time of diagnosis, and whether invasive implants are present. Patients should be evaluated by a gynecologic oncologist. At NCCN Member Institutions, patients may be initially evaluated with an undiagnosed pelvic mass or with an established diagnosis of ovarian cancer of LMP. NCCN Panel Members are less likely to recommend aggressive surgery after surgical staging; observation is one of several possible approaches. 

\[361,444\]

Patients with an LMP lesion who desire to maintain their fertility may undergo surgery limited to a USO (preserving the uterus, contralateral ovary, and contralateral Fallopian tube) at the time of comprehensive staging. 

\[141,142,445\]

If the patient does not desire fertility-sparing surgery, observation or standard ovarian cancer debulking surgery is recommended. However, data do not show increased survival with lymphadenectomy and omentectomy for LMP, although upstaging does occur. 

\[446,447\]

For patients with known LMP disease who had incomplete previous surgery and/or were incompletely staged at the time of their initial laparotomy, recommendations depend on whether invasive implants are present and whether fertility preservation is desired (see **Primary Treatment for Incomplete Previous Surgery** in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). Patients who want to preserve their fertility should have comprehensive fertility-sparing surgical staging (category 2B) if not previously done. Some investigators feel that the appearance of invasive implants on the peritoneal surfaces in patients with ovarian LMP tumors portends a less favorable prognosis; therefore, postoperative chemotherapy (category 2B) with the same regimens used for epithelial ovarian cancer can be considered for these patients (see **Primary Treatment** in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). 

\[444,442,448\]

However, the benefit of chemotherapy, either IP or IV, is controversial in ovarian LMP tumors. The significance of invasive implants remains under investigation. 

\[361,449\]

The benefit of postoperative chemotherapy has not been demonstrated for patients who have no microscopically demonstrable invasive implants; therefore, observation is recommended for these patients. 

\[450\]

Observation is an option for all patients although it may be a category 2B recommendation depending on the setting (see **Primary Treatment** for Ovarian Low Malignant Potential Tumors).

**Follow-up**

Treatment recommendations after comprehensive staging depend on the presence or absence of invasive implants. The initial therapeutic approach for patients having invasive implants may include observation or, alternatively, patients may be treated with the same chemotherapeutic regimens used for epithelial ovarian cancer (category 2B for postoperative chemotherapy) (see **Primary Treatment** in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). 

\[449\]

Patients with no invasive implants should be observed and monitored (see **Monitoring/Follow-Up** in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors). 

\[444,451\]

Patients who chose fertility-sparing surgery should be monitored by ultrasound examinations if necessary. After childbearing is completed, completion surgery should be considered (category 2B). 

\[361\]

**Relapse**

At the time of clinical relapse, a surgical evaluation and debulking are recommended if appropriate. Patients who have invasive carcinoma, either low or high grade, may be treated with epithelial ovarian cancer regimens (category 2B for low grade); those with invasive implants that are of LMP can be treated using the recommendations for primary disease (see **Primary Chemotherapy/Primary Adjuvant Therapy** in the NCCN Guidelines for Ovarian Low Malignant Potential Tumors).
Observation is recommended for those with noninvasive disease. Chemotherapy (either IP or IV) has not been shown to be beneficial in treatment of ovarian LMP tumors; therefore, chemotherapy has a category 2B recommendation in the NCCN Guidelines.361,449

Recommended Readings


& References marked with this symbol provided the basis for the algorithms.
References


31. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-


89. Greene MH, Feng Z, Gail MH. The importance of test positive predictive value in ovarian cancer screening. Clin Cancer Res


98. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011;43:420-432. Available at: [link]


102. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: [link]


332. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent


404. Loehrer PJ, Sr., Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell


450. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a